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Resumo 
 
 
Staphylococcus aureus é uma das principais causas de infeção e a 
vancomicina o antibiótico de eleição para o seu tratamento. Em 2011 foi 
descoberto o gene mecC em isolados de Staphylococcus aureus resistentes à 
meticilina, um gene 69% semelhante ao gene mecA. Também recentemente 
foi descrito um fenómeno designado de “MIC creep”, que traduz o aumento da 
concentração mínima inibitória da vancomicina dentro do intervalo de 
susceptibilidade. Os objectivos do presente trabalho incluíram avaliar a 
prevalência global do gene mecC em isolados de Staphylococcus aureus 
resistentes à meticilina e o fenómeno de “MIC creep” numa perspectiva global, 
recorrendo a técnicas de meta-analise. Em Portugal, a investigação deste 
fenómeno é ainda residual e como pode apresentar características regionais, 
este trabalho pretendeu também avaliar a sua presença em isolados de 
Staphylococcus aureus resistentes à meticilina no Centro Hospitalar Baixo 
Vouga, Aveiro. 
Na avaliação da prevalência do gene mecC obtivemos uma prevalência global 
de 0.009 (95% CI = 0.005–0.013). Apesar da prevalência ser rara e, ausente 
em Portugal, é de extrema importância monitorizar a sua possível presença em 
isolados de Staphylococcus aureus resistentes à meticilina.  
Na avaliação do fenómeno de “MIC creep”, a nível global, os resultados 
obtidos não sugeriram a presença deste fenómeno. Os resultados mostraram 
um valor médio de concentração mínima inibitória da vancomicina de 1,19 
mg/L e de 1,20 mg/L, determinados por Etest e microdiluição em caldo, 
respectivamente. A nível regional, os nossos resultados não mostraram 
evidência de “MIC creep” mas descobriram diferenças nas metodologias 
aplicadas para determinar o valor da concentração mínima inibitória da 
vancomicina. 
Quer com a pesquisa do gene mecC, quer com a avaliação dos valores de 
concentração mínima inibitória da vancomicina, a finalidade do presente 
trabalho assenta na necessidade de compreender melhor a resistência das 
infeções hospitalares aos antibióticos numa das principais bactérias 
responsável por infeções nosocomiais e alertar atempadamente, quer os 
clínicos para a possibilidade de um cenário de resistência à vancomicina, quer 
o laboratório de microbiologia para a possibilidade da existência de estirpes 
portadoras do novo gene de resistência.  
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Abstract 
 
Staphylococcus aureus is a major cause of infection and vancomycin the gold 
standard for its treatment. In 2011, mecC gene was discovered in methicillin-
resistant Staphylococcus aureus, this gene shares 69% nucleotide homology 
with mecA gene. Also in recent years it has been described a phenomenon 
called "MIC creep", which describes the increase of the minimum inhibitory 
concentration of vancomycin within susceptibility range.  
The aims of this work included the evaluation of the overall prevalence of mecC 
gene and the worldwide phenomenon of “MIC creep” using meta-analysis 
techniques. Since that in Portugal this investigation is still residual and because 
this is a phenomenon with regional characteristics, it was also assessed the 
presence of “MIC creep” in Staphylococcus aureus strains of Centro Hospitalar 
Baixo Vouga, Aveiro. 
For the evaluation of mecC gene it was obtained an overall prevalence of 0.009 
(95% CI = 0005-0013). Despite the rare prevalence of this gene and absence 
of suspected strains, it is of utmost importance in clinical and epidemiological 
terms to screen this new form of methicillin-resistant Staphylococcus aureus.  
For the evaluation of global evidence of vancomycin “MIC creep”, our results do 
not suggest the presence of this phenomenon. The results obtained showed 
that mean values of vancomycin Minimum Inhibitory Concentration, of all 
methicillin-resistant Staphylococcus aureus isolates reported, were 1.19 mg/L 
and 1.20 mg/L determined by Etest and Broth Microdilution method, 
respectively. At the regional level, our results showed no evidence of “MIC 
creep” but described differences in methodologies applied to determine 
vancomycin Minimum Inhibitory Concentration.  
Either with the evaluation of the Minimum Inhibitory Concentration of 
vancomycin values or with research of the mecC gene in Staphylococcus 
aureus, this work highlights the need to better understand the resistance of 
nosocomial infections to antibiotics and to alert clinicians to the possibility of 
resistance to vancomycin scenario and the microbiology laboratories for the 
risk of new strains carrying the resistance gene. 
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Part	I. Introduction		
	
1 Motivation		Antimicrobial	 resistance	 is	 one	 of	 the	 great	 problems	 of	 clinical	microbiology.	Your	detection	is	required	for	clinical	antimicrobial	susceptibility	categorization,	infection	and	public	health	purposes.	Antimicrobial	resistance	of	Gram-negative	bacteria	 is	 widely	 studied,	 but	 less	 developed	 for	 Gram-positive	 bacteria.	 The	rapid	acquisition	of	antibiotic	resistance	by	Staphylococcus	aureus	(S.aureus)	is	a	significant	problem	for	treatment	of	human	infections	caused	by	this	organism.	
S.aureus	is	a	highly	successful	opportunistic	pathogen,	a	frequent	colonizer	of	the	skin	 and	 mucosa	 of	 humans	 and	 animals	 and	 can	 produce	 a	 wide	 variety	 of	diseases.	 Actually,	 from	 all	 the	 known	 staphylococcal	 species,	 S.aureus	 is	 the	most	virulent.	Regardless	 the	big	number	of	 antistaphylococcal	 antibiotics	 that	are	available,	its	ability	to	adapt	makes	it	one	of	the	principal	causes	of	morbidity	or	 even	 mortality.	 This	 awareness,	 allied	 with	 the	 emergence	 of	 two	 new	problems,	the	discovery	of	a	new	gene	in	S.aureus	and	a	new	phenomenon	of	MIC	creep	in	vancomycin	and	the	important	role	of	clinical	laboratory	to	monitoring	these	situations,	are	the	main	motivations	of	my	research.			 	
Methicillin resistant Staphylococcus aureus: mecC gene and vancomycin susceptibility 	
		2	
2 Problem	definition		
S.aureus	 is	 an	 important	 human	 pathogen	 and	 was	 first	 recognized	 as	 the	etiological	 agent	 of	 suppurative	 abscesses	more	 than	130	 years	 ago	 (1).	 These	infections	 range	 from	 mild	 skin	 and	 soft-tissue	 infections	 to	 life-threatening	endocarditis,	 chronic	 osteomyelitis,	 pneumonia	 or	 bacteremia,	 which	 are	associated	with	 significant	morbidity	 and	mortality	 (2).	 The	 advent	 and	use	 of	antibiotics	 such	 as	 penicillin	 and	 methicillin	 in	 the	 mid	 20th	 century	 initially	proved	 to	 be	 effective	 against	 S.aureus.	 However,	 this	 microorganism	 rapidly	acquired	 resistance	 to	 these	 antibiotics	 and	 infections	with	 penicillin-resistant	
S.aureus	 and	methicillin-resistant	S.aureus	(MRSA)	appear	and	were	difficult	 to	treat.	 Although	 progress	 has	 been	made,	MRSA	 remains	 a	 significant	 threat	 to	human	health	globally	(1).		In	the	decade	of	60s,	when	the	resistance	to	methicillin	was	detected	in	S.aureus,	the	glycopeptide	antibiotics	where	selected	as	the	gold	standard	to	threat	some	severe	 infections	 of	 MRSA.	 Vancomycin	 was	 especially	 used	 (3,	 4).	 A	phenomenon	named	“MIC	creep”	was	described	in	recent	years	denoting	a	slow	but	 steady	 increase	 in	 vancomycin	 Minimum	 Inhibitory	 Concentration	 (MIC)	observed	over	time	(4,	5).	Poor	clinical	outcomes,	like	delayed	response,	bigger	rate	 of	 replace,	 extended	 duration	 of	 hospital	 admission	 or	 even	mortality	 are	being	associated	to	patients	with	isolates	that	reveal	MIC	creep	(6-8).	The	visible	growth	in	vancomycin	MIC	in	MRSA	isolates	that	was	noticed	in	recent	years	can	anticipate	the	appearance	of	isolates	entirely	resistant.	The	pool	of	publications	related	to	MIC	creep	showed	some	inconsistencies	about	this	phenomenon	and	is	important	 understand	 this	 phenomenon	 as	 a	 regional	 problem,	 as	 a	 global	problem	 or	 as	 a	 problem	 that	 don’t	 exist	 because	 treatment	 response	 can	 be	influenced	by	increased	in	vancomycin	MIC	value.		At	 the	 side	 of	 this	 problem	 it	was	 discovery	 a	 new	mecA	 gene	 homolog,	mecC	gene,	that	was	found	in	isolates	from	both	humans	and	animals.	This	gene	shares	69%	 nucleotide	 homology	 with	mecA,	 the	 gene	 responsible	 for	 resistance	 to	methicillin	(9).	The	detection,	antimicrobial	susceptibility	testing,	and	treatment	for	mecCMRSA	are	not	 different	 from	other	MRSA	 strains.	However,	molecular	
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techniques	such	as	detection	of	MRSA	with	Polimerase	Chain	Reaction	(PCR)	or	slide	agglutination	 tests	do	not	detect	mecCMRSA.	The	use	of	 these	 techniques,	for	detection	or	for	confirmation	of	MRSA,	can	lead	to	false-negative	results,	and	
S.aureus	will	be	incorrectly	diagnosed	as	methicillin	susceptible.	There	are	some	public	health	concerns	about	this	new	gene	(mecC)	due	to	the	fact	that	either	the	tests,	phenotypic	or	genotypic,	are	not	sufficient	to	detect	this	gene	(10).		With	 the	 discovery	 of	 the	 mecC	 gene	 in	 S.aureus	 and	 the	 description	 of	 the	phenomenon	 “vancomycin	 MIC	 creep”	 the	 treatment	 response	 in	 case	 of	 the	infections	with	this	microorganism	could	be	compromised.				 	
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3 State	of	the	art		
3.1 Staphylococcus	aureus			Alexander	 Ogston,	 in	 1882,	 described	 Staphylococci	 and	 classified	 as	
Staphylococcus	(from	 the	Greek	words	 staphylos	 [“grape”]	 and	kokkos	 [“berry”	or	“seed”])	(11).	Two	years	 later,	Friedrich	J.	Rosenbach,	reported	2	pigmented	colonies	 of	 staphylococci	 and	 suggest	 the	 nomenclature	 Staphylococcus	 albus	(Latin	for	“white”)	and	S.aureus	(from	the	Latin	aurum	[“gold”])	(12).		Nowadays,	 from	 all	 the	 known	 staphylococcal	 species,	 S.aureus	 is	 the	 most	virulent.	 Its	great	versatility	makes	this	microorganism	a	big	cause	of	mortality	and	morbidity	despite	all	the	effective	antibiotics	that	are	available	(2).	S.aureus	is	 a	 pluripotent	 pathogen	 and	 toxin-mediated	 and	 non–toxin-mediated	mechanisms	are	used	by	it	to	cause	disease.	This	organism	creates	a	large	range	of	 infections,	nosocomial	and	community-based	 that	 can	go	 from	a	 simple	 skin	and	soft	tissue	infections	(SSTIs)	to	systemic	infections	(13).		
S.aureus	is	present	on	the	population	and	constitutes	the	normal	microbial	flora	so	big	number	of	healthy	persons	(25-50%)	are	colonized	with	it	continuously	or	during	 a	 period	 of	 time	 (14).	 The	 biggest	 rates	 of	 colonization	 are	 amongst	patients	with	insulin-dependent	diabetes,	HIV-infected,	individuals	submitted	to	haemodialysis	and	patients	with	some	kind	of	skin	damage.	The	colonization	 is	more	usual	on	the	anterior	nares	but	other	parts	can	also	be	colonized	like	the	skin,	 axilla,	 vagina,	 oropharynx	 and	 perineum.	 All	 of	 these	 colonization	 sites	become	a	deposit	of	 strains	 for	 future	 infections	 (2,	15).	 It	 is	 responsible	 for	 a	high	 number	 of	 community-based	 infections	 of	 the	 skin,	 soft	 tissues	 and	respiratory	 or	 infective	 endocarditis	 (15).	 Home	 infusion	 therapy,	 that	 keeps	growing	 nowadays,	 is	 also	 responsible	 for	 some	 cases	 of	 community-acquired	infections	(2).		Overall,	S.aureus	is	responsible	for	the	majority	of	surgical	wound	infections	and	has	 one	 of	 the	 biggest	 percentages	 of	 all	 the	 nosocomial	 infections	 (16).	 Some	individuals	 that	 are	 infected	 with	 S.aureus	 obtained	 the	 strains	 from	environmental	 exposures	 or	 other	 people	 but	 the	most	 common	 cause	 is	with	
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their	own	colonisations	(15).	Transmission	is	very	frequently	due	to	the	hands	of	hospital	personnel,	which	transfer	strains	between	patients	(13).				
3.1.1 Pathogenesis	of	Infection		In	 the	 pathogenesis	 of	 S.aureus	 infections	 there	 are	 five	 different	 stages:	colonization,	 local	 infection,	 systemic	 dissemination	 and/or	 sepsis,	 metastatic	infection	 and	 toxinosis	 (17).	 	 This	microorganism	 is	 highly	 pathogenic	 due	 its	virulence	 factors,	 structural	 and	 secreted	 products,	 playing	 a	 role	 in	 the	pathogenesis	of	infection.				
3.1.2 Regulation	and	Virulence	determinants		
S.aureus	 is	 equipped	 with	 regulatory	 systems	 that	 sense	 environmental	conditions	 and	 respond	 by	 fine-tuning	 the	 expression	 of	 given	 metabolic	 and	virulence	determinants	(17,	18).	At	least	three	families	of	regulatory	elements	interlink	to	adjust	gene	expression	to	 the	 specific	 environmental	 conditions:	 first,	 two	 component	 regulatory	systems,	 of	 which	 agr	 is	 a	 paradigm;	 second,	 DNA-bindings	 proteins,	 largely	represented	by	the	Sar	family	of	proteins	and	third,	small	regulatory	RNAs	(19).	
agr	 functions	 as	 a	 quorum	 sensing	 control	 that	 reacts	 to	 bacterial	 density,	allowing	the	preferential	expression	of	surface	adhesins	during	the	exponential	phase	of	growth	and	switching	to	the	expression	of	exoproteins	during	the	post	exponential	and	stationary	growth	phases	(20,	21).		Sar	 stands	 for	 staphylococcal	 accessory	 regulator.	 It	 is	 important	 locus	 that	encodes	 a	 DNA-binding	 protein,	 SarA,	 positively	 controls	 agr	 and	 directly	regulates	adhesion	genes	(22).		Small	RNAs	(sRNA)	are	increasingly	recognized	as	major	players	in	regulation	of	gene	expression	(19).			
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3.1.3 Cell	surface	determinants	involved	in	pathogenesis			
S.aureus	is	extremely	well	equipped	in	surface	factors	and	secreted	proteins	that	mediate	host	colonization	and	disease	(table	I).	Biofilm	 is	 an	 extracellular	 polysaccharidic	 and	 proteinaceous	 network	 that	gathers	 bacterial	 communities	within	 a	mechanically	 cohesive	 scaffold.	 Biofilm	trapped	 bacteria	 are	 inactive	 and	 thus	 phenotypically	 tolerant	 to	 antibiotic	induced	killing.	His	formation	is	a	major	therapeutic	problem.	Biofilm	production	was	mainly	described	in	S.aureus	in	the	settings	of	colonization	of	catheters	and	biomaterials	(19,	23).	The	 majority	 of	 clinical	 S.aureus	 strains	 (>90%)	 elaborate	 a	 polysaccharidic	capsule.	 Capsule	 type	 5	 and	 type	 8	 are	 responsible	 for	 up	 to	 75%	 of	 clinical	infections,	 they	 are	 both	 antiphagocytic	 and	 can	 increase	 virulence	 in	 several	animal	models	(19).		Surface	 adhesins,	 confer	 adherence	 to	 a	 variety	 of	 host	matrix	 proteins.	 These	microbial	 surface	 components	 reacting	 with	 adherence	 matrix	 molecules	 are	reassemble	 under	 the	 acronym	 MSCRAMM	 “Microbial	 Surface	 Components	Recognizing	Adhesive	Matrix	Molecules”.	Most	 are	 covalently	bound	 to	 the	 cell	wall	 peptidoglycan	 (24).	 Relevant	 MSCRAMMs	 for	 pathogenesis	 include	clumping	 factor	 B	 for	 colonization	 of	 nasal	 epithelia,	 clumping	 factor	 A	 and	fibronectin-binding	proteins	A	and	B	 for	endocarditis,	 collagen-binding	protein	for	 osteomyelitis	 and	 protein	 A	 for	 immune	 escape	 and	 promotion	 of	experimental	osteoarthritis	(18).	Teichoic	 and	 lipoteichoic	 acids,	 represents	 up	 to	 50%	 of	 the	 dry	 weight	 of	purified	staphylococcal	walls.	They	have	a	physiologic	role	of	great	 importance	in	 cell	 wall	 metabolism	 and	 are	 probably	 the	 site	 of	 attachment	 of	 cell	 active	enzymes	and	others	proteins	(19,	25).		Peptidoglycan	is	a	highly	conserved	constituent	of	the	Gram-positive	envelope.	Is	a	major	scaffold	for	anchoring	most	MSCRAMMs.	It	plays	a	role	in	pathogenesis	(19).			
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3.1.4 	Secreted	enzymes	and	hemolysins		
S.aureus	 produces	 a	 number	 of	 exoenzymes,	 membrane-active	 proteins	(hemolysins	and	leucocidins)	and	toxins	that	are	involved	in	disease	mechanism.	Exoenzymes	 encompass	proteases	 and	 lipases,	witch	 are	destructive	 regarding	host	 tissues	 and	 useful	 for	 getting	 nutrient	 to	 the	 invading	 bacterium	 (19).	
S.aureus	 has	 a	 minimum	 of	 four	 hemolysins	 referred	 to	 as	 α-hemolysin,	 β-hemolysin,	 γ-hemolysin,	 δ-	 hemolysin.	 They	 can	 lyse	 erythrocytes	 and	 other	eukaryotic	cells.	They	are	all	encoded	on	the	chromosome	and	are	subject	to	agr	regulation	(19).	Panton-Valentine	Leukocidin	(PVL),	unlike	the	other	hemolysins,	is	 encoded	 by	 a	 mobile	 phage	 that	 can	 transfer	 PVL	 to	 others	 strains.	 The	prevalence	rate	of	PVL	is	usually	low	(≤	2%)	in	MSSA	and	health	care-associated	MRSA	 (26),	whereas	 it	 is	 present	 in	 almost	 100%	of	 isolates	 of	 CA-MRSA	 (27,	28).	PVL-producing	S.aureus	is	associated	with	skin	and	soft	tissue	infection	and	severe	haemorrhagic	pneumonia	in	children	and	young	adults	(18).				
Table	I:	Virulence	factors	of	Staphylococcus	aureus	and	their	proposed	pathogenic	
mechanisms.	Adapted	(18)	
Involved	in	evading/destroying	host	defenses	 Microcapsule	Protein	A	Coagulase	Fatty	acid–metabolizing	enzyme	Leukocidin	and/or	g-toxin	Involved	in	tissue	invasion/penetration	 Proteases	Nucleases	Lipases	Hyaluronate	lyase	Staphylokinase	Involved	in	toxin-mediated	disease	and/or	sepsis	 Toxic	shock	syndrome	toxin	Enterotoxins		Cytolytic	toxins	(a,	b,	g,	and	d)	Induce	specific	toxinosis		 Toxic	shock	syndrome	toxin	Enterotoxin		Exfoliative	toxin	Attach	to	endothelial	cells	and	basement	membrane		 Binding	proteins	for	fibrinogen,	fibronectin,	laminin,	collagen,	
 		
Methicillin resistant Staphylococcus aureus: mecC gene and vancomycin susceptibility 	
		8	
3.1.5 Clinical	Manifestations			
S.aureus	 is	 responsible	 for	 local	 infections	or	 acts	 at	 a	distance	by	 secretion	of	toxins	 (table	 II)	 (19).	 The	 SENTRY	 antimicrobial	 surveillance	 program	 that	collects	 data	 from	 United	 States	 (US),	 Europe,	 Canada,	 Latin	 America	 and	 the	Western	 Pacific,	 reported	 the	 following	 distributions	 of	 S.aureus	 infections:	39,2%	of	SSTI;	23,2%	of	lower	respiratory	tract	infections;	22%	of	bloodstream	infections,	 including	 infective	 endocarditis	 and	 15,6%	 of	 other	 infections,	including	infections	of	the	urinary	tract,	brain	and	abdominal	cavity	(29).		
S.aureus	SSTIs	include	primary	pyoderma	(folliculitis,	 furuncles,	carbuncles	and	impetigo)	and	soft	tissue	infections	(cellulitis,	erysipelas	and	pyomyositis).	They	are	commonly	classified	according	to	the	anatomic	structure	involved:	infection	of	 the	 epidermis	 (impetigo);	 infection	 of	 the	 superficial	 dermis	 (folliculitis);	infection	 of	 deep	 dermis	 (furuncles,	 carbuncles	 and	 hidradenitis	 suppurative)	and	infection	of	subcutaneous	cellular	tissues	(cellulitis,	fasciitis,	erysipelas	and	pyomyositis)	 (2).	 The	 diagnosis	 of	 SSTIs	 is	 usually	 made	 clinically.	 The	 basic	anatomic	 lesion	 induced	 by	 S.aureus	 is	 a	 pyogenic	 exudate	 or	 an	 abscess.	 The	more	 severe	 infections	 are	 usually	 associated	 with	 deeper	 tissue	 invasion.	Superficial	infections	can	often	be	treated	with	local	care,	surgical	drainage	and,	rarely,	 systemic	 antibiotics.	 On	 the	 other	 hand,	 deeper	 infections	 such	 as	erysipelas,	 lymphangitis,	 lymphadenitis,	 cellulitis	 and	 necroting	 fasciitis	 are	severe	 diseases	 that	 may	 be	 life	 threatening.	 They	 require	 hospitalization,	systemic	antibiotic	therapy	and	prompt	surgical	drainage	(13,	19).		Bloodstream	infection	(BSI)	is	defined	as	one	or	several	positive	blood	cultures	associated	with	general	symptoms	such	as	fever	or	hypotension	(13).	S.aureus	is	the	second	most	common	cause	of	BSI,	with	an	overall	contemporary	incidence	rate	 between	20	 and	30	 episodes	 per	 100,000	 inhabitants	 per	 year	 across	 the	world	 (30).	 BSI	 is	 usually	 divided	 in	 two	 categories:	 nosocomial	 BSI,	 in	which	positive	 blood	 cultures	 occur	 two	 days	 or	 more	 after	 hospital	 entry	 and	community	acquired	BSI,	which	occurs	in	the	community	or	before	two	days	of	hospitalization	 (19).	 These	 are	 commonly	 related	 with	 the	 presence	 of	intravascular	 catheters	 or	 devices,	 procedures	 in	 contaminated	 sites,	 surgical	site	 infection	 and,	 sometimes,	 S.aureus	 pneumonia	 (19).	 A	 therapy	 with	
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antibiotics	 should	 be	 started	 if	 S.aureus	 is	 detected	 in	 any	 blood	 culture.	Additionally,	blood	should	be	sampled	for	follow-up	cultures	and	determination	of	the	origin	and	dimension	of	the	infection	(31).	An	important	consideration	in	the	 bacteraemia	 is	 the	 risk	 of	 endocarditis.	 The	 infective	 endocarditis	 is	uniformly	 lethal	 if	 not	 treated	 with	 antibiotics,	 with	 or	 without	 surgery.	 This	disease	typically	follows	an	acute	course,	with	multiple	peripheral	septic	emboli,	valve	destruction,	myocarditis	and	mixed	cardiogenic	and	septic	shock	(19).		In	the	hospital,	S.aureus	is	becoming	the	most	frequent	pathogen	responsible	for	nosocomial	 pneumonia.	 In	 community,	 pneumonia	 occurs	 primarily	 in	 elderly	patients	 (>	 75	 years)	 admitted	 from	 nursing	 homes	 but	 also	 in	 patients	 with	predisposing	factors,	such	as	diabetes	and	alcoholism	(13,	19).		
S.aureus	 is	 the	 most	 common	 pathogen	 in	 all	 three	 major	 classes	 of	osteoarticular	 infection,	 namely,	 osteomyelitis,	 native	 joint	 septic	 arthritis	 and	prosthetic	joint	infection	(13).				
Table	II:	Common	illnesses	caused	by	Staphylococcus	aureus.	Adapted	(2).	
Skin	and	Soft	Tissue	Infections	 Folliculitis		Furuncle,	carbuncle	Cellulitis	Impetigo	Mastitis		Surgical	wound	infections		
Musculoskeletal	Infections	 Septic	arthritis		Osteomyelitis		Pyomyositis		Psoas	abscess		
Respiratory	Tract	Infections	 Ventilator-associated	or	nosocomial	pneumonia		Septic	pulmonary	emboli		Postviral	pneumonia		Empyema		
Bacteremia	and	Its	Complications	 Sepsis	Septic	shock		Metastatic	foci	of	infection	(kidney,	joints,	bone,	lung)		Infective	endocarditis		
Infective	Endocarditis	 Injection	drug	use	associated		Native-valve			Prosthetic-valve		Nosocomial		Toxin-Mediated	Illnesses	 Toxic	shock	syndrome		Food	poisoning			Staphylococcal	scalded-skin	syndrome			
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3.2 Methicillin	Resistant	Staphylococcus	aureus			In	the	beginning	of	the	40s,	the	launch	of	penicillin	G	improved	significantly	the	prognosis	 but	 in	 1942	 resistant	 strains	 started	 to	 emerge	 (32).	 A	 penicillinase	enzyme	 that	 hydrolyzed	 the	 β-lactam	 ring	 and	 inactivated	 the	 drug	 was	 their	resistance	mechanism.	This	enzyme	is	encoded	by	blaZ,	which	typically	resides	on	 a	 large	 transposon	on	a	plasmid.	The	 rate	of	 resistance	 to	penicillin	 is	now	greater	 than	 90%	 in	 human	 S.aureus	 isolates,	 making	 the	 use	 of	 penicillin	essentially	useless	to	treat	these	infections	(33).		In	 order	 to	 stop	 the	 spread	 of	 this	 resistance	 to	 penicillin	 a	 semisynthetic	penicillinase-resistant	 β-lactam	 that	 was	 named	 Methicillin	 was	 created.	 This	new	antibiotic	was	launch	in	1959	with	the	commercial	name	“Celbenin”	but	the	earliest	reports	of	resistant	strains	started	to	appear	 just	after	 the	next	year	 in	London	(34).	The	isolates	had	the	same	phage	type	and	included	isolates	taken	on	 the	 same	day	 from	a	patient	and	a	nurse	on	 the	 same	ward.	This	discovery	advertised	 to	 the	 emergence	 of	 methicillin-resistant	 S.aureus	 (MRSA)	 as	 a	nosocomial	pathogen.	MRSA	emerged	during	the	1960s	in	many	countries,	even	tin	 countries	where	methicillin	was	 not	 available,	 and	 it	 is	 now	 very	 frequent	worldwide	(35).		Despite	 that	 Methicillin	 is	 out	 of	 the	 market	 and	 the	 clinic,	 the	 term	 MRSA	continued	to	exist.	It	is	used	to	identify	the	resistance	to	all	β-lactams	(except	the	last	 generation	 of	 cephalosporins).	 The	 infection’s	 treatment	 can	 become	 even	more	complicated	because	MRSA	can	become	resistant	to	one	or	more	different	antimicrobials	(36).	This	resistance	includes	vancomycin,	considered	one	of	the	last	 treatment	 options	 for	 severe	 MRSA	 infections,	 and	 other	 relatively	 new	agents	like	linezolid	and	daptomycin	(33,	37).			
3.2.1 Mobile	resistance	element	SCCmec			Microorganisms	 are	 capable	 of	 spreading,	 creating	 ecological	 reservoirs,	colonizing	and	causing	diseases.		
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The	mobile	genetic	elements	that	are	involved	in	the	resistance	and	virulence	in	staphylococci	 are	 bacteriophages,	 chromosomal	 cassettes,	 plasmids,	 insertion	sequences	and	transposons	(38).		MRSA	contains	one	resistance	 island	called	staphylococcal	cassette	chromosome	(SCCmec),	 where	 is	 the	 genetic	 element	 that	 confers	 resistance	 to	 methicillin.	SCCmec	is	an	exogenous	piece	of	DNA	that	may	vary	between	15	and	60kb	(19)	and	your	basic	elements	are	the	ccr	gene	complex,	the	mec	gene	complex	and	the	joining	region	(J	region)	(38,	39)	(figure	1).	Is	located	near	the	replication	origin	of	 the	 chromosome	 of	 Staphylococcus	 and	 inserted	 at	 the	 insertion	 site	 attB	(located	 at	 the	3’	 end	of	orfX).	 It	 is	 a	mobile	 genetic	 element	 carrying	 the	mec	gene	 (mecA,	mecB	 and	mecC)	 along	with	 the	 genes	 that	 control	 its	 expression,	
mecR1	 (encoding	 the	 signal	 transduce	protein	MecR1)	 and	mecI	 (encoding	 the	repressor	 protein	MecI),	 and	 acts	 as	 a	 carrier	 to	 exchange	 genetic	 information	between	Staphylococcus	strains	(9,	40,	41).		The	ccr	gene	complex	is	composed	by	ccr	gene(s)	and	surrounding	open	reading	frames	 (ORFs)	 several	 of	 them	 without	 any	 known	 function.	 Three	phylogenetically	distinct	ccr	 genes,	ccrA,	ccrB	and	ccrC,	have	been	 identified	 in	
S.aureus	 (38,	 42).	 Additionally,	 SCCmec	 is	 integrated	 to	 the	 chromosome	 of	
Staphylococcus	strains	by	the	accurate	excision	and	integration	of	ccrAB	or/and	
ccrC.	According	to	the	different	kinds	of	ccrAB	or/and	ccrC,	the	ccr	gene	complex	was	 classified	 into	 8	 allotypes:	 type	 1	 carrying	 ccrA1	 and	 ccrB1	 genes,	 type	 2	carrying	ccrA2	and	ccrB2	genes,	 type	3	carrying	ccrA3	and	ccrB3	genes,	 type	4	carrying	 ccrA4	 and	 ccrB4	 genes,	 type	 5	 carrying	 ccrC1	 gene,	 type	 6	 carrying	
ccrA5	 and	 ccrB3	 genes,	 type	 7	 carrying	 ccrA1	 and	 ccrB6	 genes,	 and	 type	 8	carrying	ccrA1	and	ccrB3	genes	(43).		The	mec	 gene	 complex	 is	 constituted	 of	mecA,	mecB	 and	mecC,	 its	 regulatory	genes	(mecR1	and	mecI)	and	associated	insertion	sequences.	Is	classified	into	5	classes	 take	 into	 account	 the	 regulatory	 genes	 located	 upstream	 and	downstream	of	the	mec	gene	and	the	difference	of	insertion	sequences	(43).	The	class	 A	mec	 gene	 complex	 is	 the	 prototype	 complex,	which	 contains	mecA,	 the	complete	 mecR1	 and	 mecI	 regulatory	 genes	 upstream	 of	 mecA,	 the	 hyper-variable	 region	 (HVR)	and	 insertion	sequence	 IS431	downstream	of	mecA.	The	class	 B	mec	 gene	 complex	 is	 composed	 of	mecA,	 a	 truncated	mecR1	 resulting	
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from	the	insertion	of	IS1272	upstream	of	mecA,	HVR	and	IS431	downstream	of	
mecA.	 The	 class	 C	mec	 gene	 complex	 contains	mecA,	 truncated	mecR1	 by	 the	insertion	of	IS431	upstream	of	mecA,	HVR	and	IS431	downstream	of	mecA.	There	are	two	distinct	class	C	mec	gene	complexes;	 in	the	class	C1	mec	gene	complex,	the	IS431	upstream	of	mecA	has	the	same	orientation	as	the	IS431downstream	of	mecA	(next	to	HVR),	while	in	the	class	C2	mec	gene	complex,	the	orientation	of	IS431	upstream	of	mecA	is	reversed.	The	class	D	mec	gene	complex	is	composed	of	mecA	and	ΔmecR1,	but	does	not	carry	an	 insertion	sequence	downstream	of	ΔmecR1	(42,	44).		Apart	 from	 ccr	 and	mec,	SCCmec	has	 some	 not	 essential	 components	 called	 J-region	(Junkyard-region).	 	Differences	in	the	J	regions	leads	to	some	variants	of	SCCmec	 types	 (38,	 45).	 On	 the	 basis	 of	 location	 in	 SCCmec,	 the	 J	 region	 was	classified	into	J1,	J2	and	J3	regions	(43).		Currently,	 based	 on	 the	 nature	 of	mec	 and	 ccr	 genes	 complexes	 and	 different	subtypes	 in	 accordance	 with	 their	 J	 region	 DNA	 segments,	 eleven	 types	 of	SCCmec	(type	I	to	XI)	are	known	(table	III)	(46).					
	
Figure	1:	Basic	structure	of	SCCmec.	SCCmec	is	bracketed	by	direct	repeats	(DRs)	that	contain	integration	site	sequence	(ISS).	A	pair	of	inverted	repeats	(IRs)	is	present	at	the	termini	of	SCCmec.	Two	critical	gene	complexes,	ccr	and	mec	are	present,	and	the	other	regions	are	designated	J1,	J2,	and	J3.	Adapted	(40).							 	
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Table	III:	Current	SCCmec	types.	Adapted	(43)	SCCmec	type	 mec	gene	complex	 Structure	of	mec	gene	complex	 ccr	gene	complex	 ccr	genes	
I	 Class	B	 IS1272-ΔmecR1-mecA-IS431	 Type	1	 ccrA1,	ccrB1	
II	 Class	A	 mecI-mecR1-mecA-IS431	 Type	2	 ccrA2,	ccrB2	
III	 Class	A	 mecI-mecR1-mecA-IS431	 Type	3	 ccrA3,	ccrB3	
IV	 Class	B	 IS1272-ΔmecR1-mecA-IS431	 Type	2	 ccrA2,	ccrB2	
V	 Class	C2	 IS1431-mecA-	ΔmecR1-IS431	 Type	5	 ccrC1	
VI	 Class	B	 IS1272-ΔmecR1-mecA-IS431	 Type	4	 ccrA4,	ccrB4	
VII	 Class	C1	 IS1431-mecA-ΔmecR1-IS431	 Type	5	 ccrC1	
VIII	 Class	A	 mecI-mecR1-mecA-IS431	 Type	4	 ccrA4,	ccrB4	
IX	 Class	C2	 IS1431-mecA-	ΔmecR1-IS431	 Type	1	 ccrA1,	ccrB1	
X	 Class	C1	 IS1431-mecA-	ΔmecR1-IS431	 Type	7	 ccrA1,	ccrB6	
XI	 Class	E	 blaZ-mecA-mecR1-mecI	 Type	8	 ccrA1,	ccrB3			
3.2.2 Mechanism	of	resistance	in	Methicillin	Resistant	Staphylococcus	aureus			Peptidoglycan	is	the	main	structural	component	of	the	cell	wall,	and	it	consists	of	glycan	 strands	 made	 of	 repeating	 N-acetylglucosamine	 and	 N-acetylmuramic	acid	 disaccharides	 connected	 by	 peptide	 cross-links	 between	N-acetylmuramic	acid	moieties	on	adjacent	strands	(33).	In	 summary,	 the	 steps	 in	 cell	 wall	 biosynthesis	 in	 staphylococci	 are	 N-acetylglucosamine	and	N-acetylmuramic	acid	disaccharides	attached	via	a	β-1,4-glycosidic	 bond	 to	 the	 reducing	 end	 of	 the	 growing	 peptidoglycan	 chain	 in	 a	transglycosylation	reaction.	The	recently	included	repeating	unit	is	cross-linked	by	 a	 transpeptidation	 reaction	 to	 a	 stem	 peptide	 in	 an	 adjacent	 peptidoglycan	strand.	Both	transglycosylation	and	transpeptidation	are	carry	out	by	penicillin-binding	proteins	(PBPs).	The	stem	peptide	composition	varies	between	bacterial	species,	 but	 is	 typically	 L-Ala–γ-D-Glu–L-Lys–D-Ala–D-Ala	 in	 gram-positive	bacteria	(47).		Differently	from	the	penicillin	resistance	of	S.aureus,	methicillin	resistance	is	not	mediated	by	a	plasmid-borne	β-lactamase	and	it	was	described	in	early	studies	as	 intrinsic	 resistance	 (33).	 Other	 bacterial	 pathogens	 with	 identical	 intrinsic	
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resistance	to	β-lactams	are	related	to	changes	in	PBPs,	either	in	their	amount	or	in	their	affinity	for	β-lactams,	so	attention	turned	to	PBPs	in	MRSA	as	the	likely	mechanism	(33).		
S.aureus	 generally	 produces	 four	 PBPs.	 These	 enzymes	 are	 bounded	 to	cytoplasmic	membrane	 and	 their	 functions	 are	 the	 assembly	 and	 regulation	 of	the	latter	stages	of	the	cell	wall	biosynthesis	(48).	These	enzymes	are	susceptible	to	 modification	 by	 β-lactam	 antibiotics	 leading	 to	 the	 bacterial	 cell	 wall	biosynthesis	 inhibition	and	bacterial	death.	PBP2a	 is	refractory	to	the	action	of	β-lactam	 antibiotics	 because	 is	 capable	 of	 assuming	 the	 functions	 of	 the	 four	typical	 PBPs	 in	 the	 presence	 of	 β-lactam	 antibiotics	 (41).	 In	 brief,	 MRSA	 is	resistant	 to	 almost	 all	 β-lactam	 antibiotics.	 In	 methicillin-sensitive	 S.aureus	(MSSA),	the	β-lactam	antibiotics	bind	to	the	native	PBPs	that	are	present	in	the	
S.aureus	 cell	 wall,	 which	 results	 in	 the	 disruption	 of	 the	 synthesis	 of	 the	peptidoglycan	layer	and	the	S.aureus	will	not	survive	(48).	On	the	other	hand,	in	MRSA	the	β-lactam	antibiotics	are	not	able	to	bind	due	to	the	presence	of	PBP2a,	leading	to	the	increase	of	MRSA	because	there	is	no	disruption	of	peptidoglycan	layer	synthesis	(49,	50).		PBP2A	is	encoded	by	an	acquired	gene	mecA	gene	located	on	the	chromosome	of	MRSA	 (41)	 and	 SCCmec	 carry	 this	 gene	 and	 was	 responsible	 for	 the	 widely	disseminated	among	staphylococcal	species	(51).			
mecA	 is	 regulated	 by	 the	 repressor	 MecI	 and	 the	 transmembrane	 β-lactam-sensing	 signal-transducer	 MecR1,	 which	 are	 divergently	 transcribed.	 MecI	represses	the	transcriptions	of	mecA	and	mecR1–mecI	if	a	β-lactam	antibiotic	is	absent.	 However,	 with	 antibiotic,	 mecR1	 is	 autocatalytically	 cleaved	 and	 the	metalloprotease	 domain	 (located	 in	 the	 cytoplasmic	 part	 of	mecR1)	 becomes	active.	This	metalloprotease,	which	 is	 bounded	 to	 the	mecA	gene,	 cleaves	mecI	enabling	the	transcription	of	mecA	and	the	production	of	PBP2a	(figure	2)	(38,	50,	51).				
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Figure	2:	Model	of	the	salient	features	of	mecA	regulation.	
(A)	Absence	of	β-lactams:	the	binding	of	the	repressor	MecI	to	this	region	stops	transcription	from	the	mec	operator.	(B)	Presence	of	β-Lactams:	are	detected	by	their	binding	to	the	penicillin-binding	domain	(PBD)	of	MecR1.	MecR1	is	autocatalytically	cleaved	and	the	metalloprotease	domain	(MPD)	becomes	active.	This	MPD,	which	is	bound	to	the	mecA,	cleaves	mecI	allowing	the	transcription	of	mecA	and	the	production	of	PBP2a.	Adapted	(33).			
3.2.3 Epidemiology	of	Methicillin	Resistant	Staphylococcus	aureus		Surveillance	 of	 MRSA	 gives	 relevant	 information	 on	 the	 extent	 of	 the	 MRSA	epidemic,	 identifying	 priorities	 for	 infection	 control	 and	 the	 need	 for	 any	adjustment	 in	 antimicrobial	 drug	 policy	 and	 guides	 intervention	 programs.	 In	Europe,	 there	 is	 only	 one	 initiative	 that	 continuously	 monitors	 antimicrobial	resistance,	 the	 European	 Antimicrobial	 Surveillance	 System	 (EARSS).	 This	international	 network	 connects	 national	 surveillance	 systems	 and	 provides	results	of	routine	antimicrobial	susceptibility	tests	(AST)	following	standardized	protocols	that	can	be	comparable	and	validated	between	a	representative	set	of	laboratories	of	multiple	countries	(52).		From	the	start	of	the	year	1999	to	the	end	of	2002,	EARSS	received	AST	results	of	53,264	 S.aureus	 blood	 isolates	 from	 27	 different	 countries.	 20%	 of	 the	 total	isolates	 were	 identified	 as	 methicillin	 resistant.	 MRSA	 was	 more	 frequently	isolated	from	men	(21%)	than	from	women	(18%,	p	<	0.001).	In	average	patients	with	 a	 blood	 culture	 positive	 for	 MRSA	 were	 older	 than	 patients	 with	 MSSA	(mean	age,	65.3	[SD	18.7]	versus	58.6	[SD	23.4],	p	<	0.001).	Patients	admitted	to	intensive	care	units	have	the	highest	proportion	of	MRSA	(35%)	(53).		
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Geographically	there	is	an	obvious	difference	between	the	north	and	the	south	of	Europe.	 The	 countries	 in	 the	 northern	 Europe	 have	 a	 lower	MRSA	 prevalence	when	compared	with	the	southern	countries	(54).		Before	 the	 appearance	 of	 antibiotics,	 S.aureus	 bacteremia	was	 fatal	 in	most	 of	cases.	 In	 a	 study	of	 cases	 in	 the	beginning	of	 1940s,	 the	mortality	 rate	 on	122	consecutive	patients	was	82%	and	98%	in	patients	older	than	50	years.		Nowadays,	 S.aureus	 is	 carried	 on	 the	 skin	 or	 mucous	 membranes	 of	approximately	 25	 to	 35%	 of	 healthy	 humans	 	 (55).	 The	 MRSA	 and	 penicillin-resistant	 S.aureus	 evolution	 is	 very	 similar	 (56).	 MRSA	 is	 currently	 pandemic,	with	 dissemination	 of	 Hospital	 Acquired	 –	 MRSA	 (HA-MRSA)	 clones	 from	 the	1960s,	 Community	 Acquired	 –	 MRSA	 (CA-MRSA)	 clones	 from	 the	 1990s	 and	Livestock	Acquired	–	MRSA	(LA-MRSA)	clones	from	the	2000s	(55).		In	some	European	countries,	such	as,	Greece,	Austria,	Ireland,	France	and	the	UK	the	prevalence	of	HA-MRSA	decreased	 in	the	 last	years.	The	MRSA	clones	most	frequently	collected	from	all	continents	from	1961	to	2008	were	CC5,	CC8,	CC22,	CC30	and	CC45	(35,	57).	The	most	common	in	Europe	and	USA	is	CC45	(55).	In	the	 last	decades,	MRSA	infections	were	principally	confined	to	hospitals,	but	the	 emergence	 of	 CA-MRSA	 infections	 shaped	 the	 epidemiology	 of	 S.aureus	leading	to	the	replacement	of	HA-MRSA	clones	by	community-associated	MRSA	(58).	 Between	 2009-2010	 Tavares	 A,	 et	 al.	 studied	 a	 total	 of	 1,487	 S.aureus	isolates	collected	from	16	Portuguese	healthcare	institutions	located	in	different	geographic	 regions	 of	 Portugal,	 reporting	 that	 MRSA	 clones	 present	 in	 the	community	were	clones	typically	found	in	hospitals	(10,	51).	The	 study	 of	 Rolo,	 J.,	 et	 al	 aimed	 to	 describe	 the	 population	 structure	 of	 CA-
S.aureus	 in	European	countries,	 including	some	of	 the	most	populous	countries	in	 Europe	 like	 The	 Czech	 Republic,	 Spain,	 The	 Netherlands,	 Greece,	 United	Kingdom,	 Sweden,	 Hungary,	 Bulgaria,	 Denmark,	 France,	 Poland,	 Romania,	Portugal,	 Finland,	 Slovakia	 and	 Italy.	 The	 combination	 of	 the	 results	 obtained	showed	that	59%	of	isolates	were	related	to	epidemic	CA-S.aureus	clones,	while	27%	 were	 related	 to	 HA	 clones.	 In	 CA-S.aureus	 epidemic	 clones,	 58%	 were	MRSA,	 37%	 were	 related	 to	 USA300	 and	 36%	 were	 related	 to	 the	 European	epidemic	clones	(51).		Based	on	the	2015	ECDC	(European	Centre	for	Disease	Prevention	and	Control)	
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report,	 Portugal	 is	 the	 third	 European	 country	 with	 the	 highest	 prevalence	 of	MRSA	 (46,8%),	 nevertheless	 is	 one	 of	 the	 countries	 that	 prevalence	 remains	stable	 in	 the	 last	 years	 (Figure	 3).	 The	 MRSA	 isolates	 were	 more	 frequent	patients	older	than	65	years	old	(54).		Taking	 into	 account	 the	 prevalence	 of	 MRSA	 in	 European	 countries,	 the	prevalence	in	Portuguese	hospitals	has	been	close	to	50%	for	more	than	10	years	and	 remains	 one	 of	 the	 highest	 in	 Europe	 (Figure	 4)	 (54),	 so	 is	 extremely	important	 to	 our	 country	 to	 design	 national	 intervention	 and	 prevention	strategies.	 	 It	 is	also	 important	 to	monitor	changes	 in	epidemiology	of	S.aureus	infections	 (humans	 and	 animals)	 in	 order	 to	 provide	 the	 correct	 treatment,	control	the	infection	effectively	and	study	the	evolution	of	the	species	(55).					
Figure	3:	Evolution	of	MRSA	in	the	three	countries	with	highest	prevalence.	Adapted	(54).			
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Figure	4:	Proportion	of	Methicillin	Resistant	Staphylococcus	aureus	isolates	in	
participating	countries	in	2015.	Adapted	(54).	
		
3.2.4 Diagnostic	detection	of	Methicillin	Resistant	Staphylococcus	aureus		In	 a	 clinical	 microbiology	 laboratory,	 the	 correct	 detection	 and	 diagnosis	 of	MRSA	 is	 extremely	 important	 to	 select	 the	 correct	 treatment	 and	 for	 infection	control.	 The	 molecular	 identification	 of	 mecA	 gene,	 normally	 using	 PCR,	 or	PBP2a,	typically	using	antibody	detection	with	slide	agglutination	assays	are	the	recommended	 methodologies	 for	 MRSA	 detection.	 These	 methodologies	 are	consistent	 because	 both	 mecA	 and	 PBP2a	 have	 a	 high	 level	 of	 conservation	between	MRSA	isolates	(10,	59).	Disk	 diffusion	 method	 consistently	 predicts	 methicillin	 resistance	 thought	 the	cefoxitin	 screening.	 The	 MRSA	 isolates	 are	 resistant	 to	 cefoxitin	 when	 MIC	 is	greater	than	4mg/L	(60).			
3.2.5 The	emergence	of	mecC	Methicillin	Resistant	Staphylococcus	aureus		In	2007,	was	 isolated	a	S.aureus	 LGA251	from	bovine	mastitis	 in	England	which	was	 phenotypically	MRSA	but	methodologies	 applied	 to	 detect	mecA	 gene	 and	
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PBP2a	 were	 negative	 (61).	 Genome	 sequencing	 of	 this	 isolate	 found	 that	 the	strain	carried	a	new	mecA	homologue	(mecALGA251)	 is	only	69%	identical	to	the	conventional	 mecA	 at	 the	 DNA	 level	 and	 the	 encoded	 PBP2a	 was	 only	 63%	identical	at	the	amino	acid	level.	These	facts	explain	the	resistance	described	and	the	negative	results	obtained	in	the	two	methodologies	applied	(10,	62).		
mecALGA251	is	located	within	a	SSCmec	element	inserted	into	the	3’	region	of	orfX	like	 the	 traditional	 mecA	 (10).	 In	 the	 end	 of	 2009,	 SCCmec	 sequence	 from	LGA251	was	classified	and	given	the	designation	of	type	XI	SCCmec.	In	2012	the	gene	mecALGA251	 was	 renamed	 to	mecC	 (9).	 The	 designation	mecB	 (divergent	homologue	of	mecA)	was	already	described	in	Macrococcus	caseolyticus	(9,	10).		There	are	significative	distinctions	 in	 the	performance	of	 the	proteins	encoded	by	mecC	and	mecA	in	methicillin	resistance.	The	protein	PBP2amecC	was	bound	by	β-lactams	 but	 indicated	 greater	 affinity	 for	 oxacillin	 when	 compared	 with	cefoxitin,	while	PBP2amecA	showed	less	affinity	(63).			
3.2.6 Diagnostic	detection	of	mecC	Methicillin	Resistant	Staphylococcus	aureus		
mecCMRSA	 have	 a	 high	 probability	 of	 being	 correctly	 identified	 as	MRSA	with	antimicrobial	 susceptibility	 testing	 (64).	 Using	 automated	 system	 Vitek2,	
mecCMRSA	produce	a	different	profile	when	compared	with	mecAMRSA.	When	the	 antibiotics	 oxacillin	 and	 cefoxitin	 are	 tested,	 mecAMRSA	 is	 classically	resistant	 to	 both	 and	 mecCMRSA	 is	 resistant	 to	 cefoxitin	 but	 susceptible	 to	oxacillin,	nevertheless	they	are	reported	as	MRSA	(65).		In	 clinical	 laboratories,	 the	 main	 problem	 is	 when	 the	 identification	 or	confirmation	of	MRSA	is	done	using	molecular	detection	of	the	mecA	gene.	Using	this	method	needs	 to	 consider	 the	 incorporation	 of	mec	 gene	primers	 that	 are	able	 to	 amplify	 both	mecA	 and	mecC	 or	 the	 addition	 of	mecC-specific	 primers.	Also,	 slide	 agglutination	 assays	 for	 mecA	 encoded	 PBP2a	 will	 fail	 when	identifying	mecCMRSA.	 Using	 only	 the	 slide	 agglutination	 assays	 produce	 false	negative	 results	and	 is	essential	 the	confirmation	by	PCR	(10).	 In	brief,	 clinical	microbiology	laboratories	must	know	that	there	is	a	potential	diagnostic	gap	and	
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different	 tests	 should	 be	 used	 to	 correctly	 and	 rapidly	 identify	mecCMRSA	 as	MRSA.				
3.2.7 Epidemiology	of	mecC	Methicillin	Resistant	Staphylococcus	aureus			Multiple	theories	regarding	the	origin,	epidemiology	and	the	impact	of	the	MRSA	isolates	carrying	the	mecC	gene	were	created	since	its	discovery.	Several	studies	were	 implemented	 aiming	 to	 understand	 this	 new	 gene	 present	 in	 S.aureus	strains.	 The	 discovery	 of	mecCMRSA	 in	 dairy	 cows	 in	 England,	 described	 by	Garcia	Alvarez,	et	al.,	 indicates	 that	 these	animals	might	provide	a	 reservoir	of	infection	(62).		The	few	available	reports	on	this	topic	show	that	data	on	mecCMRSA	in	humans	and	animals	are	now	becoming	available,	allowing	some	important	 information	on	the	epidemiology	and	prevalence	of	mecCMRSA.	At	 the	time	of	 this	analysis,	
mecCMRSA	was	reported	 in	14	European	countries	and	has	been	 isolated	 from	14	 host	 species.	 MRSA	 harbouring	 mecC	 has	 been	 reported	 from	 humans,	livestock,	 domestic	 and	 wild	 animals	 (10,	 66).	 The	 multilocus	 sequence	 types	CC130	and	ST425	are	the	major	lineages	found	in	mecCMRSA	isolates	(10).		
 
 
 	
3.3 Vancomycin			The	 vancomycin	was	 discovery	 by	 Eli	 Lilly	 during	 the	 50s.	 Since	 its	 discovery,	more	 than	 50	 years	 ago,	 the	 interest	 in	 vancomycin	 keeps	 increasing.	 Studies	published	in	the	last	years	showed	that	there	is	more	knowledge	regarding	this	antibiotic	and	its	use	(3).	Vancomycin	became	the	gold	standard	in	treatment	of	serious	MRSA	infections	after	the	emergence	of	these	strains	(3,	4).	Lilly	isolated	an	organism	called	Amycolatopsis	orientalis	(previously	known	as	Streptomyces	
orientalis	and	Nocardia	orientalis)	from	a	sample	of	dirt	sent	by	a	missionary	that	
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visited	 the	 Borneo	 Island	 in	 Asia.	 This	 organism	 produced	 a	 substance	 that	inhibited	gram-positive	organisms	(compound	05865).	Its	brown	colour	gave	it	the	 name	 “Mississippi	 mud”.	 The	 first	 clinical	 trials	 started	 in	 the	 middle	 of	1950s	and	the	U.S.	Food	and	Drug	Administration	(FDA)	approved	 it	 for	use	 in	1958	(3,	67).				
3.3.1 Mechanism	of	Vancomycin	Action		In	 Gram-positive	 bacteria,	 vancomycin	 inhibits	 the	 cell	 wall	 synthesis	 with	 a	different	 mechanism	 than	 β-lactam	 antibiotics	 (68).	 While	 these	 antibiotics	inhibit	 cell	 wall	 synthesis	 by	 binding	 to	 the	 transpeptidase	 active	 site	 of	penicillin	 binding	 proteins,	 vancomycin	 binds	 to	 the	 C-terminal	 D-Ala-D-Ala	residue	of	the	peptidoglycan	precursor	and	forms	a	stable,	noncovalent	complex,	which	prevents	 the	 use	 of	 the	precursor	 for	 cell	wall	 synthesis	 (Figure	5)	 (67,	69).	 To	 inhibits	 late-stage	 of	 peptidoglycan	 biosynthesis,	 vancomycin	 acts	outside	of	cytoplasmatic	membrane	(68).		The	 vancomycin	 complex	 involves	 hydrogen	 bonds	 between	 the	 peptide	component	of	vancomycin	and	the	D-Ala-D-Ala	residue.	If	any	process	interferes	with	 the	 binding	 of	 the	 drug	 with	 D-Ala-D-Ala	 residues	 in	 the	 cell	 wall,	 the	effectiveness	of	the	vancomycin	decrease	(67).	In	S.	aureus,	the	main	location	for	cell	wall	synthesis	is	the	division	septum,	so	vancomycin	has	to	diffuse	to	the	tip	of	the	division	septum	to	bind	to	peptidoglycan	precursors.	This	location	and	the	distance	of	this	diffusion	depend	on	the	cell	cycle	(67,	69).		
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Figure	5:	Peptidoglycan	biosynthesis	and	mechanism	of	action	of	vancomycin.	Binding	of	the	antibiotic	to	the	C-terminal	d-Ala–d-Ala	of	late	peptidoglycan	precursors	prevents	reactions	catalyzed	by	transglycosylases	and	transpeptidases	(69).	
		
3.3.2 Therapeutic	vancomycin	drug	monitoring		Some	parameters	 either	pharmacokinetic	or	pharmacodynamic	were	proposed	to	supervise	vancomycin.	These	parameters	including	time	(t),	the	concentration	of	 vancomycin	 remains	above	 the	MIC	 (t>MIC),	 the	 ratio	of	 the	area	under	 the	serum	drug	concentration	–versus-	time	curve	and	the	MIC	(AUC/MIC)	and	the	ratio	 of	 the	 maximum	 serum	 drug	 concentration	 (Cmax)	 and	 the	 MIC	(Cmax/MIC).		The	parameter	AUC/MIC	was	recommended	by	the	reviews	of	pharmacokinetics	and	 pharmacodynamics	 and	 a	 ratio	 ≥	 400	 was	 defined	 as	 a	 target	 to	 obtain	success	with	vancomycin	(70).	Nevertheless,	is	difficult	to	obtain	various	serum	vancomycin	concentrations	to	determine	the	AUC	and	applied	this	values	in	ratio	AUC/MIC.	 So,	 the	 trough	 serum	 concentration	 monitoring	 is	 the	 most	appropriate	 and	 practical	 technique	 to	 monitor	 the	 vancomycin	 (3,	 70).	 It	 is	recommended	a	total	trough	serum	vancomycin	concentration	of	15–20	mg/L	to	try	 to	 increase	clinical	outcomes	 for	complicated	 infections.	That	concentration	
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should	obtain	an	AUC/MIC	of	400	 in	a	great	number	of	patients	 if	 the	MIC	 is	1	mg/L	(70,	71).		Other	important	parameter	to	determine	the	success	of	a	given	dosage	regimen	is	 Vancomycin	 MIC.	 This	 value	 ideally	 should	 be	 provided	 by	 the	 clinical	microbiology	laboratory	but	the	methodologies	used	to	determine	antimicrobial	susceptibility	 (disk	diffusion,	 automated	microdilution,	 Etest	method)	 limit	 the	correct	report	of	vancomycin	MIC	value	by	some	laboratories	(70).				
3.3.3 Toxicity			Many	of	the	adverse	events	attributed	to	vancomycin	in	the	past	were	probably	attributable	to	 impurities	present	 in	older	preparations	that	were	present	until	the	mid	1980s	(4).		In	the	first	trials	was	described	an	association	between	the	usage	of	vancomycin	and	 a	 little	 toxicity.	 Rash,	 chills	 and	 venous	 irritations	 were	 observed	 but	believed	to	be	related	to	the	infusions.	Ototoxicity	was	reported	but	considered	to	be	related	to	elevated	serum	concentrations	 in	 individuals	with	renal	 failure	(72).	 These	 problems	 were	 more	 frequent	 associated	 with	 the	 use	 of	 early	preparations	of	vancomycin,	 therefore	they	were	considered	to	be	the	result	of	impurities	in	the	compound	(3,	73,	74).		Infusion-related	reactions	associated	with	vancomycin	have	been	well	described	and	referred	to	as	the	“red	man”	syndrome.	It	is	characterized	by	tingling	or	itch	associated	 with	 flushing	 of	 the	 upper	 body.	 It	 usually	 occurs	 within	 a	 few	minutes	 of	 the	 start	 of	 the	 infusion	 and	 resolves	 soon	 after	 cessation	 of	 the	infusion.	 In	 cases	 where	 signs	 persist	 after	 cessation	 of	 the	 infusion	 or	hypotension	is	prominent,	hypersensitivity	should	be	considered	(71,	73).		Vancomycin	 rarely	 cases	 interstitial	nephritis,	it	 remains	 controversial	whether	modern	 preparations	 of	 vancomycin	 cause	 nephrotoxicity.	 Studies	 have	 used	inconsistent	definitions	and	had	difficulty	establishing	the	temporal	relationship.	They	 are	 also	 confounded	 by	 the	 use	 of	 other	 nephrotoxins,	 other	 potential	causes	 of	 nephrotoxicity	 such	 as	 sepsis	 and	 underlying	 comorbidities.	 Several	
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studies	have	shown	an	association	between	higher	 trough	concentrations	 (>15	mg/L)	and	nephrotoxicity,	but	it	is	unclear	whether	vancomycin	is	the	cause	or	simply	an	indicator	of	renal	toxicity	(70).	A	consensus	definition	for	toxicity	has	been	 proposed	 as	 repeated	 measured	 increases	 in	 creatinine	 >44	 mmol/L	 or	50%	 above	 baseline	 after	 several	 days	 of	 vancomycin	 therapy	 in	 the	 lack	 of	another	 reason.	 Is	 recommended	 that	 clinical	 approach	 first	 consider	 other	causes	 and	 ensure	 adequate	 hydration	 before	 attributing	 nephrotoxicity	 to	vancomycin	(70).				
3.3.4 Mechanisms	of	resistance	to	Vancomycin			The	vancomycin	activity	is	determined	by	specificity	of	substrate	of	the	enzymes	involved	 in	 structure	 of	 peptidoglycan	 precursors	 (69).	 Operons	 that	 encode	enzymes	are	responsible	for	the	resistance	to	vancomycin.	First,	with	modifying	the	vancomycin-binding	 target	with	 the	 synthesis	of	 low-affinity	precursors,	 in	which	 the	C-terminal	d-Ala	 residue	 is	 replaced	by	d-lactate	 (d-Lac)	or	d-serine	(d-Ser)	and	second	removing	the	vancomycin-binding	target,	with	elimination	of	the	high-affinity	precursors	that	are	generally	produced	by	the	host	(69).		High	levels	of	resistance	to	vancomycin	and	teicoplanin	characterize	VanA-type	resistance	and	it	is	presently,	the	only	one	detected	in	S.aureus.	This	resistance	is	based	 on	 modification	 of	 the	 vancomycin-binding	 target	 and	 is	 mediated	 by	transposon	 Tn1546	 that	 encodes	 9	 polypeptides	 which	 can	 be	 distributed	 in	various	 functional	 groups:	 transposition	 (ORF1	 and	 ORF2),	 regulation	 of	resistance	 gene	 expression	 (VanR	 and	 VanS),	 synthesis	 of	 the	 d-Ala-d-Lac	depsipeptide	 (VanH	 and	 VanA),	 and	 hydrolysis	 of	 peptidoglycan	 precursors	(VanX	and	VanY)	(69).	A	 dehydrogenase	 (VanH)	 reduces	 pyruvate	 to	 d-Lac	 and	 the	 VanA	 ligase	catalyzes	the	formation	of	an	ester	bond	between	d-Ala	and	d-Lac.	The	d-Ala-d-Lac	 depsipeptide	 formed	 replaces	 the	 d-Ala-d-Ala	 dipeptide	 in	 peptidoglycan	synthesis,	 a	 substitution	 that	 decreases	 the	 affinity	 of	 the	 molecule	 for	glycopeptides.	The	removal	of	the	susceptible	precursors	that	terminate	in	d-Ala	
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prevents	the	interaction	of	vancomycin	with	its	target	(3,	69).	Two	enzymes	are	involved	in	this	process,	the	VanX	D,D-dipeptidase,	which	hydrolyzes	the	d-Ala-d-Ala	 dipeptide	 synthesized	by	 the	host	 d-Ala-d-Ala	 ligase	 (Ddl),	 and	 the	VanY	D,D-carboxypeptidase,	 which	 removes	 the	 C-terminal	 d-Ala	 residue	 of	 late	peptidoglycan	precursors	when	elimination	of	d-Ala-d-Ala	by	VanX	is	incomplete	(figure	6)	(69).		Conjugal	 transfer	 of	 plasmids	 that	 have	 acquired	 Tn1546-like	 elements	 by	transposition	seems	to	be	responsible	for	the	increase	of	glycopeptide	resistance	in	 enterococci	 (69).	 Either	 in	 vitro	 or	 in	 vivo	 it	 was	 possible	 transfer	 Van	resistance	 genes	 from	 Enterococcus	 spp	 to	 S.aureus	 (75).	 In	 Michigan,	Pennsylvania	 and	 New	 York	 were	 described	 MRSA	 isolates	 with	 high	 or	moderate	 levels	of	 resistance	 to	vancomycin	after	acquisition	of	 the	vanA	gene	cluster	(76-78).		 	
	
Figure	6:	VanA-type	glycopeptide	resistance.			
3.3.5 Vancomycin	resistance	and	vancomycin	MIC	creep			Despite	 being	 approved	 for	 use	 in	 humans	 in	 1958,	 vancomycin	 became	 an	antibiotic	of	choice	for	treatment	of	MRSA	infections	in	hospital	settings	only	in	the	late	1980s	(3).	
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In	1997,	an	S.aureus	clinical	isolate	carried	by	a	Japanese	man	was	found	to	have	a	 very	 low	 susceptibility	 to	 vancomycin.	 This	 isolate	 was	 the	 first	 reported	Vancomycin	Intermediate	S.aureus	(VISA)	(79).	VISA	is	typically	associated	with	hospitalization,	 persistent	 infection,	 prolonged	 vancomycin	 treatment	 and/or	treatment	failure.	The	VISA	phenotype	is	frequently	preceded	by	an	intermediate	phenotype	known	in	the	clinical	laboratory	as	heterogeneous	VISA	(hVISA)	(67).	An	hVISA	phenotype	refers	to	a	mixed	cell	population,	derived	originally	from	a	single	 colony	 of	 S.aureus,	 in	 which	 the	 majority	 of	 cells	 have	 little	 or	 no	resistance	 to	 vancomycin	 (MIC	 ≤	 2	 mg/L)	 and	 a	 sub-population	 of	 cells	 is	resistant	to	the	antibiotic	at	the	level	of	VISA	(MIC	≥	4	mg/L)	(67).		Resistance	 to	 vancomycin	was	discovered	 in	 enterococci	 in	 the	1980s	and	 this	finding	caused	significant	concern	with	regard	to	the	future	use	of	vancomycin	as	an	 effective	 treatment	 for	MRSA	 (80).	 The	 first	 Vancomycin	Resistant	S.aureus	(VRSA)	isolate	in	the	United	States	was	reported	in	2002	(81).		Complete	 vancomycin	 resistance	 in	 S.aureus	 is	 conferred	 by	 the	 vanA	 operon	encoded	 on	 transposon	 Tn1546,	 originally	 a	 part	 of	 a	 vancomycin-resistant	enterococci	 (VRE)	 conjugative	 plasmid	 [48].	 S.aureus	 can	 acquire	 enterococcal	plasmids	during	discrete	conjugation	events.	Vancomycin	resistance	in	S.aureus	is	maintained	by	retaining	an	original	enterococcal	plasmid	or	by	a	transposition	of	 Tn1546	 from	 the	 VRE	 plasmid	 into	 a	 staphylococcal	 resident	 plasmid.	 Risk	factors	for	acquisition	appear	to	be	prior	co-infection	or	colonization	with	MRSA	and	 vancomycin	 resistant	 enterococci,	 substantial	 comorbidity	 and	 prolonged	vancomycin	use	(82).	MRSA	 with	 decreased	 vancomycin	 susceptibility	 are	 categorized	 as	heteroresistant,	 intermediate	 or	 resistant	 to	 vancomycin	 (83).	 This	 distinction	has	 not,	 however,	 been	 applied	 by	 the	 European	 Committee	 for	 Antimicrobial	Susceptibility	 Testing	 (EUCAST)	 which	 defines	 all	 S.aureus	 strains	 with	 a	vancomycin	MIC	of	4	mg/L	as	vancomycin	resistant	(60).		A	 phenomenon	 named	 “MIC	 creep”	was	 described	 in	 recent	 years	 indicating	 a	slow	but	stable	increase	in	vancomycin	MIC	observed	over	time,	from	values	of	0.5–0.75	 mg/L	 to	 levels	 of	 1.25–1.5	 mg/L	 (4,	 5).	 The	 visible	 growth	 in	vancomycin	MIC	in	MRSA	isolates	that	was	noticed	in	recent	years	can	anticipate	the	 appearance	 of	 isolates	 entirely	 resistant.	 The	 gradual	 increase	 in	 MICs	 to	
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vancomycin	amongst	susceptible	S.aureus	 strains,	are	not	 the	same	 in	different	parts	of	the	world	and	are	not	necessarily	universally	present	(82).	Poor	clinical	outcomes,	 like	 delayed	 response,	 bigger	 rate	 of	 replace,	 extended	 duration	 of	hospital	 admission	 or	 even	 mortality	 are	 being	 associated	 with	 patients	 with	isolates	 that	 reveal	MIC	 creep	 (6-8).	 The	 type	 of	microbiological	 susceptibility	test	 used	 (Etest,	 broth	microdilution	 (BMD)	or	 automated	 system),	 the	 type	of	
S.aureus	strain	or	the	type	of	patient	population	evaluated	can	be	compromising	the	 results	 of	 MIC	 creep	 (6,	 84).	 BMD	 continues	 to	 be	 the	 gold	 standard	 for	measuring	MIC	 (85).	 The	 literature	 is	 not	 consensual	 about	 this	 phenomenon,	there	are	studies	where	vancomycin	MIC	creep	 is	reported	with	BMD	(85)	and	Etest	methods	(86),	and	studies	that	found	no	vancomycin	MIC	creep	when	using	the	 same	methods	 (87).	 The	pool	 of	 publications	 related	 to	MIC	 creep	 showed	inconsistencies,	with	studies	that	report	increases	in	the	mean	vancomycin	MIC	and	studies	that	do	not	confirm	these	findings	in	MRSA.					
 
3.4 Antimicrobial	susceptibility	testing	in	Microbiology	Laboratory		The	major	responsibility	of	clinical	microbiology	laboratory	is	the	evaluation	of	Antimicrobial	Susceptibility	Tests	(AST).		
In	 vitro	 AST	 are	 performed	 on	 pathogenic	 and/or	 resistant	 microorganisms.	These	 tests	 are	 fundamental	 to	 monitor	 the	 resistance,	 epidemiological	susceptibility	and	comparisons	between	new	and	existing	agents	(88).	Breakpoints	defined	by	regulatory	entities	and	professional	groups	are	often	the	same.	 The	 Food	 and	 Drug	 Administration	 (FDA)	 and	 Clinical	 and	 Laboratory	Standards	 Institute	 (CLSI),	 currently	 reviewed	 the	 breakpoints.	 In	 Europe,	 the	MIC	breakpoints	have	been	defined	by	EUCAST	(60).				
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3.4.1 Dilution	methods	for	AST		The	minimal	antibiotics’	concentration	that	is	necessary	to	inhibit	or	ideally	kill	microorganisms	can	be	obtained	using	dilution	methods.	Antibiotics	are	typically	tested	at	2-fold	doubling	(log2)	serial	dilutions,	with	the	lowest	concentration	of	each	antibiotic	 that	 inhibits	visible	growth	of	organisms	designated	as	 the	MIC	(89,	90).		Typically	 broth	 dilution	 testing	 include	 macro	 dilution,	 where	 the	 volumes	 of	broth	 in	 test	 tubes	 for	 each	 dilution	 are	 typically	 ≥1	 mL,	 and	 BMD,	 in	 which	antimicrobial	concentrations	are	most	frequently	of	smaller	volumes	in	96-well	microtiter	plates.	The	BMD,	is	considered	the	gold	standard	method	(88).				
3.4.2 Agar	disk	diffusion	test	for	AST		Mueller-Hinton	agar	is	the	medium	recommended	for	routine	testing,	classifying		isolates	 as	 susceptible,	 intermediate	 or	 resistant	 to	 antimicrobial	 agents.	 This	method	 makes	 easier	 the	 identification	 of	 population	 heterogeneity	 (resistant	subpopulations)	 and	 inoculum	 contamination	 (“mixed”	 cultures)	 because	 is	more	easily	detected	by	agar	than	by	broth	testing	methods	(89).		In	 this	 testing	method,	 prepared	 filter	 paper	 disks	 impregnated	with	 specified	predetermined	concentrations	of	the	antibiotics	are	applied	to	the	surface	of	an	agar	 medium	 previously	 inoculated	 with	 the	 microorganism.	 If	 the	microorganism	 inoculated	 in	 the	agar	surface	grows	around	 the	drugs	diffused	means	 that	 it	 is	 resistant	 to	 the	 antibiotic.	 In	 the	 other	 side,	 if	 the	 antibiotic	inhibit	the	growth	of	the	bacteria	resulting	in	a	inhibition	zone	around	the	drug	means	that	the	microorganism	is	susceptible	to	the	antibiotic	(88,	89).		The	 Etest	 method	 is	 used	 for	 determined	 the	 real	 MIC	 value	 in	 μg/ml,	 this	method	 is	 based	 on	 quantitative	 gradient	 of	 concentration,	 allowing	 to	determine	 the	 MIC	 between	 the	 conventional	 dilutions.	 Another	 advantage	 is	that	 gradient	 of	 the	 drug	 on	 plastic	 strips	 remains	 stable	 for	 18-24	 hours,	covering	the	critical	times	of	the	microorganisms	growth	(5).		
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3.4.3 Automated	system		The	automated	system	performs	all	the	required	steps	to	identify	and	determine	the	antimicrobial	susceptibility	profile	after	the	preparation	and	standardization	of	 the	 inoculum.	 This	 system	 reads	 the	 tests	 every	 15	minutes	 and	 provides	 a	kinetic	 analysis.	 The	 optical	 system	 combines	 multichannel	 fluorimeter	 and	photometer	readings	to	record	fluorescence,	turbidity,	and	colorimetric	signals.	The	results	are	interpreted	by	the	database	incorporated	in	the	system.	MICs	of	each	 antimicrobial	 agent	 are	 compared	 with	 MICs	 obtained	 by	 the	 reference	method	 and	 the	 susceptibility	 is	 categorized	 as	 susceptible,	 intermediate,	 or	resistant	taking	into	account	the	current	breakpoint	criteria	(91).						Considering	the	state	of	the	art	and	the	problem	definition	previously	described,	research	 objectives	were	 assumed	 and	 the	 results	 obtained	were	 described	 in	the	following	section.					
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Part	II. Research		
	
1 Objectives	of	research		 1. Perform	 a	 meta-analysis	 on	 the	 prevalence	 of	 mecCMRSA,	 based	 on	published	studies	and	study	the	presence	of	suspect	mecCMRSA	in	clinical	isolates	with	a	combination	of	two	methodologies.			 2. Evaluate	the	evidence	of	vancomycin	MIC	creep	phenomenon	recurring	to	a	meta-analysis.			3. Assess	vancomycin	MIC	distribution	for	S.aureus	infections	and	to	identify	differences	 in	 vancomycin	 MIC	 through	 the	 application	 of	 different	susceptibility	testing	methods.			The	 research	 developed	 resulted	 in	 three	 articles	 published	 in	 peer	 reviews	journals	 and	 a	 fourth	 study	 is	 submitted	 to	 peer	 review	 and	waiting	 approval	(results	will	be	presented	during	discussion	–	Part	III).	 	 	
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2 Results			Study	 number	 1:	 “Methicillin-resistant	 Staphylococcus	aureus	 carrying	 the	 new	
mecC	gene—a	meta-analysis.”		Results	 from	 the	 different	 studies	 do	 not	 provide	 a	 good	 overview	 of	 the	 real	prevalence	of	mecC	gene.	With	this	knowledge,	this	study	aimed	to	apply	meta-analysis	techniques	to	perform	an	improved	evaluation	of	the	available	data	on	overall	prevalence	of	mecCMRSA	in	humans	and	animals. 		Study	number	2:	“Evaluation	of	vancomycin	MIC	creep	in	Staphylococcus	aureus	infections	–	a	meta-analysis”	In	 an	 attempt	 to	 clarify	 inconsistencies	 in	 evaluation	 of	 MIC	 creep,	 this	 study	intended	 to	 comprehensively	 assess	 the	 evidence	 of	 MIC	 creep,	 using	 a	meta-analysis.				Study	number	3:	“Evaluation	of	vancomycin	MIC	creep	in	Staphylococcus	aureus	infections”		It	is	important	to	see	the	vancomycin	MIC	creep	linked	to	a	regional	problem	and	the	evaluation	of	their	local	susceptibility	profiles	should	be	essential	in	the	local	MRSA	 infection	 clinical	 management.	 This	 study	 assess	 the	 vancomycin	 MIC	distribution	 for	 S.aureus	 infections,	 over	 a	 period	 of	 four	 years	 in	 Aveiro,	Portugal.  	
 		 	
Methicillin resistant Staphylococcus aureus: mecC gene and vancomycin susceptibility 	
		 33	
Article	“Methicillin-resistant	Staphylococcus	aureus	 carrying	 the	
new	mecC	gene—a	meta-analysis.”		Raquel	Diaz,	Elmano	Ramalheira,	Vera	Afreixo,	Bruno	Gago	Diagnostic	Microbiology	and	Infectious	Disease,	84	(2016)	135-140	URL:	http://www.dmidjournal.com/article/S0732-8893(15)00368-5/fulltext	DOI:	10.1016/j.diagmicrobio.2015.10.014	PMID:	26652130																																					
Antimicrobial Susceptibility Studies
Methicillin-resistant Staphylococcus aureus carrying the new mecC
gene—a meta-analysis
Raquel Diaz a,⁎, Elmano Ramalheira b,1, Vera Afreixo c,2, Bruno Gago d,3
a Health Sciences Department, University of Aveiro, Institute for Research in Biomedicine–iBiMED, Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal
b Health Sciences Department, University of Aveiro, Department of Medical Microbiology, Centro Hospitalar Baixo Vouga, Av. Artur Ravara, 3814-501, Aveiro, Portugal
c Department of Mathematics, University of Aveiro, Institute for Biomedicine–iBiMED, Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal
d Health Sciences Department, University of Aveiro, Institute for Biomedicine–iBiMED, Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal
a b s t r a c ta r t i c l e i n f o
Article history:
Received 9 June 2015
Received in revised form 10 September 2015
Accepted 19 October 2015
Available online 23 October 2015
Keywords:
mecC gene
Staphylococcus aureus
Prevalence
In 2011, a newmecA gene homolog, namedmecC gene, was found in isolates from both humans and animals. The
discovery of methicillin-resistant Staphylococcus aureus (MRSA) carrying themecC gene has caused speculations
about the origin, epidemiology, and impact of these isolates. The objective of this work is to perform a meta-
analysis on the prevalence of mecC MRSA, based on previously published results. Meta-analysis showed that
the overall pooled prevalence is 0.009% (95% conﬁdence interval = 0.05–0.013) and that there was evidence
of heterogeneity (P b 0.01, I2 = 97%). In conclusion, the very low reported prevalence provides an important
baseline to monitor the epidemiology of this emerging form of MRSA.
© 2016 Elsevier Inc. All rights reserved.
1. Introduction
Staphylococcus aureus (S. aureus) was identiﬁed in the 1880s and is
recognized as the most virulent species of staphylococci. Its versatility
makes it a leading cause of morbidity and mortality, despite the large
amount of effective antistaphylococcal antibiotics. S. aureus is a poten-
tially pathogenic gram-positive bacteria causing infections that can go
from minor impact, such as skin infection, to higher impact episodes
such as postsurgical wound infections and systemic infections.
(Dennis Kasper, 2010; Deurenberg and Stobberingh, 2008).
Thismicroorganism is part of normal humanﬂora; around 20% of in-
dividuals are colonized persistently nasally, and 30% are colonized inter-
mittently. However, colonization can occur in many other locations
such as the armpits, groin, and gastrointestinal tract (Williams et al.,
1959). Colonization provides a reservoir fromwhich bacteria can be in-
troduced when host defenses are violated, for example during shaving,
by inserting a catheter or during a surgery (Diekema et al., 2001;
Wertheim et al., 2004). Colonization clearly increases the risk of subse-
quent infection in healthy individuals (Gordon and Lowy, 2008).
The vast majority of people who develop infections caused by
S. aureus are infected with their own colonizing strains; however,
these infections can also be obtained from other people or environmen-
tal exposures. Transmission results most frequently from transient col-
onization through the hands of hospital staff that carry strains from
one patient to another (DeLeo et al., 2010; McCormick et al., 2001).
Resistance to antibiotics is a well-known serious problem in medi-
cine. S. aureus has a great ability to acquire resistance to antibiotics. In
1961, Patricia Jevons reported the ﬁrst isolates of methicillin-resistant
S. aureus (MRSA), only 2 years after the clinical usage of methicillin.
(Moellering, 2012; Sung et al., 2012)
In the following decades, MRSA isolates have spread throughout the
world and can be found nowadays in many industrialized countries
(DeLeo et al., 2010). For many years, the reported cases of MRSA infec-
tions were limited to hospitals, but the exponential emergence of
community-associatedMRSA (CA-MRSA) infections changed the epide-
miology of S. aureus (Francois et al., 2004; Gerber et al., 2009) so that the
distinction between CA-MRSA and hospital-associated MRSA is
disappearing (Deurenberg and Stobberingh, 2008; Mediavilla et al.,
2012; Sung et al., 2012).
1.1. Mechanism of resistance in MRSA
Pathogens are able to spread, establish ecological reservoirs, colo-
nize, and cause disease. The mobile genetic elements involved in the
spread of resistance and virulence in staphylococci are bacteriophages,
chromosomal cassettes, plasmids, insertion sequences, and transposons
(Hanssen and Ericson Sollid, 2006).
MRSA is resistant to practically all β-lactam antibiotics, and it is
known that his resistance is caused by the production of a penicillin-
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binding protein (PBP) named PBP2A that reduces the binding afﬁnities
to β-lactam antibiotics. In methicillin-sensitive S. aureus (MSSA), β-
lactam antibiotics bind to the native PBPs that are present in the
S. aureus cell wall, which results in the disruption of the synthesis of
the peptidoglycan layer causing S. aureus death (Fuda et al., 2004). On
the other hand, in MRSA, PBP2A is present, and the binging of β-
lactam antibiotics is not possible so that the synthesis of peptidoglycan
layer occurs normally and with consequent MRSA colony development
(Berger-Bachi and Rohrer, 2002; Deurenberg and Stobberingh, 2008).
PBP2A is encoded by the genemecA located in MRSA chromosome. Se-
quencing of the region containingmecA revealed a distinct mobile ge-
netic element (SCCmec) that is present in MRSA but absent in MSSA.
SCCmec elements are highly diverse, with 11 types (I–XI) recognized
to date. (Katayama et al., 2000; Peacock and Paterson, 2015).
1.2. mecC gene in S. aureus
In 2011, a new mecA gene homolog, mecALGA251, was found in iso-
lates from both humans and animals. The International Working
Group on the Classiﬁcation of Staphylococcal Cassette Chromosome
(SCC) Elements renamed it tomecC (Ito et al., 2012).
ThemecC gene shares 69% nucleotide homology withmecA and was
found in a novel staphylococcal cassette chromosome (SCC) element
designated as SCCmec type XI (Ito et al., 2012). Until now, isolates con-
taining mecC gene have proved to be resistant phenotypically to β-
lactams but have failed to be recognized as classical MRSA with PCRs
for mecA, owing to different nucleotide composition (Kim et al., 2012;
Shore et al., 2011; Stegger et al., 2012).
The discovery ofMRSA carrying themecC genehas caused speculations
about the origin, epidemiology, and impact of these isolates. Several stud-
ies were implemented aiming at understanding this new gene present in
S. aureus strains (Garcia-Alvarez et al., 2011). The detection, antimicrobial
susceptibility testing, and treatment formecCMRSA are not different from
other MRSA strains. However, molecular techniques such as detection of
MRSA with PCR or slide agglutination tests do not detect mecC MRSA.
The use of these techniques, for primary detection or for conﬁrmation of
MRSA, can lead to false-negative results, and S. aureuswill be erroneously
diagnosed as methicillin susceptible (Garcia-Alvarez et al., 2011).
According to a study of Garcia-Alvarez et al. (2011), the discovery of
mecC MRSA in dairy cows in England suggests that these animals might
provide a reservoir of infection. Additionally, close linkswith farms or con-
tact with dairy cattle could be risk factors that increase the likelihood of
mecC MRSA carriage or infection in patients (Garcia-Alvarez et al., 2011).
This study showed thatmecC MRSA was resistant to penicillin, oxacillin,
and cefoxitin but susceptible to gentamicin, neomycin, ciproﬂoxacin, tetra-
cycline, erythromycin, clindamycin, fusidic acid, chloramphenicol,
teicoplanin, rifampicin, trimethoprim, linezolid, and mupirocin. mecC
MRSA showed negative reactions in the latex agglutination test for
PBP2a, in PCR assayswith primers formecA and in PCR assays that amplify
the SCCmec-orfX region of the SCCmec. Culture of mecC MRSA on agar
plates with andwithout adjacent discs impregnatedwith both amoxicillin
and clavulanic acid indicated that resistance was not mediated by β-
lactamase hyperproduction (Garcia-Alvarez et al., 2011). The β-
lactamase gene (blaZ) is present in SCCmecC, but the inability of
clavulanate (a β-lactamase inhibitor) to change this resistance indicates
that resistance is unlikely to be caused by β-lactamase. Themost probable
explanation for this resistance is the presence of mecA homologue in the
type XI SCCmec (Garcia-Alvarez et al., 2011; Laurent et al., 2012).
The few available reports on this topic show that data onmecCMRSA
in humans and animals are now becoming available, and relevant infor-
mation on the epidemiology and prevalence ofmecC MRSA can now be
collected. Even so, at these point, results from the different studies do
not provide a good overview of the current situation. The aim of this
study is to apply meta-analysis techniques to perform an improved
evaluation of the available data on overall prevalence ofmecC MRSA in
humans and animals.
2. Methods
2.1. Data collection
A review of the literature was conducted to identify epidemiological
data about prevalence ofmecCMRSA. The search strategywas limited to
Medline database, English language, and articles published until April
2015. The keywords as search query used in PubMed engine were
“methicillin-resistant Staphylococcus aureus”, OR “methicillin-resistant
Staphylococcus aureus [Mesh]” OR MRSA AND “mecC gene” OR “novel
mecA” OR “new mecA” OR “LGA251”.
The study hits from the search strategy were reviewed for inclusion
and exclusion criteria. Studieswere considered eligible for inclusion if it
was possible to evaluate the prevalence ofmecCMRSA in human and/or
animal infections. Data extraction was guided by a checklist assessing
clarity of aims and research questions.
The most relevant information was extracted from each eligible
study (author, title, year and country, host species, sample size, and
prevalence) and considered for the meta-analysis.
2.2. Statistical analysis
Homogeneity among studies was computed using the Cochran's Q
statistic and the I2 statistic. A signiﬁcant Q statistic suggests that the dis-
tribution of effect sizes around themean is greater than it would be pre-
dicted fromsampling error alone,whereas the I2 provides an estimate of
the proportion of the variance in the aggregate effect size that is attrib-
utable to between-studies heterogeneity, with values of 0.25, 0.50, and
0.75 indicating low, moderate, and high degrees of heterogeneity
(Johnson and Whisman, 2013).
In order to perform a secondary analysis, a subgroup analysis was
carried out, and the estimated prevalence was reported for two sub-
groups: i) infections in humans and ii) infections in animals. Due to
the signiﬁcant heterogeneity between the studies, the pooled preva-
lence for each group was estimated using the random-effects model.
MetaXL 1.0., a tool for meta-analysis in Microsoft Excel, was used to
pool individual prevalence from each study.
Publication bias was assessed using a funnel plot analysis. Funnel
plots are scatter plots that plot effect size on the X axis and the standard
error of the effect size on the Y axis and provide 95% conﬁdence inter-
vals (represented by cone-shaped lines) around the mean effect size.
If only a few studies with negative or small effect sizes are included in
the analysis or more than 5% of included studies fall outside of the con-
ﬁdence intervals, this will lead to asymmetry in the funnel plot and can
indicate publication bias (Johnson and Whisman, 2013).
3. Results
According to the results of literature search, 248 articles published
between January 2011 and April 2015 matched the searching criteria.
From this group, 51 articles related to mecC gene in S. aureus and 37
studies on the screening of mecC gene were selected. Finally, studies
with true prevalence of the mecC gene were included in the meta-
analysis (Fig. 1 and Table 1).
The estimated prevalence in the human subgroup is 0.004% (95%
conﬁdence interval [CI] = 0.002–0.007), and the estimated prevalence
in the animal subgroup is 0.10% (95% CI= 0.033–0.174). The overall es-
timated prevalence is 0.009% (95% CI = 0.005–0.013) (Fig. 2).
Publication bias was assessed using a funnel plot analysis. Visual in-
spection of a funnel plot can give an indication of publication bias. The
studies are expected to spread symmetrically about the pooled effect
size when publication bias is absent. Our study shows publication bias
using funnel plot analysis (Fig. 3).
To evaluate the robustness of our analysis, we conducted a sensitiv-
ity analysis by recalculating thepooled results of the primary analysis by
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excluding each single study in turn. Table 2 revealed that the exclusion
of any single study did not alter the overall combined result.
4. Discussion
In this work, 23 published studies from PubMed were identiﬁed as
fulﬁlling the inclusion criteria, namely, of the availability of prevalence
data on the presence ofmecCMRSA in humans, animal, or both. Studies
with true prevalence of themecC genewere also included into themeta-
analysis (Fig. 1 and Table 1), and studieswith opportunist sampling, like
that developed by Garcia-Alvarez et al. (2011), were excluded. In fact,
the amount of proper prevalence studies is so reduced that the value
of a meta-analysis cannot be really clear. However, it is the best statisti-
cal technique to evaluatemecC MRSA prevalence.
Fig. 1. Results of the literature search.
Table 1
Feature and characteristic studies included in study.
Country Host species Sample size (S. aureus) Period for the sampling Prevalence Studies references in meta-analysis (reference)
England Human 2010 October 2011–June 2012 0.45 Paterson et al. (2013)
USA Human 364 June 2009–December 2011 0 Ganesan et al. (2013)
Denmark Human 56382 National collection of SAB isolates 1960–2011;
national collection of MRSA 1988–2011;
healthy nasal carriers 2009–2010;
SAB received after August 2011
0.5 Petersen et al. (2013)
203 August 2011–October 2011 5.9 Stegger et al. (2012)
Germany Human 12691 January 2006–June 2011 0.09 Cuny et al. (2011)
3207 2004–2005; 2010–2011 0.06 Schaumburg et al. (2012)
Animal 38 Unknown 47.3 Schlotter et al. (2014)
Belgium Animal 303 August 2009–May 2011 0.99 Vandendriessche et al. (2013)
Human 41 August 2009–May 2011 0 Vandendriessche et al. (2013)
4869 2003–2012 0.18 Deplano et al. (2014)
Spain Human 5505 2008–2013 0.04 Garcia-Garrote et al. (2014)
6 January 2014 0 Gomez et al. (2015)
361 2009–2012 1.1 Porrero et al. (2014)
13 2011–2013 15 Gomez et al. (2014)
Animal 16 January 2014 68.8 Gomez et al. (2015)
601 August 2008–July 2009 0.16 Ariza-Miguel et al. (2014)
Netherlands Animal 55 October 2011–January 2012 0 van Duijkeren et al. (2014)
Switzerland Human 555 2005–2011 0 Basset et al. (2013)
Austria Human 295 2009–2013 2.0 Kerschner et al. (2014)
Animal 8 Unknown 37.5 Loncaric et al. (2014)
Finland Animal 135 2003–2008 0.74 Gindonis et al. (2013)
Sweden Animal 730 2010–2011 0.55 Unnerstad et al. (2013)
Slovenia Human 395 2006–2013 1.5 Dermota et al. (2015)
Jordan Human 56 May 2011–April 2012 0 Aqel et al. (2015)
France Animal 10 2011–2013 40 Haenni et al. (2014)
SAB = S. aureus bacteremia cases.
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At the time of this analysis,mecCMRSAwas reported in 13 European
countries and has been isolated from 14 host species (Paterson et al.,
2014). MRSA harboring mecC has been reported from humans, live-
stock, domestic, and wild animals (Loncaric et al., 2014).
After discovery of the study ofmecC gene, its prevalence became an
important public health issue. In many studies, these reports represent
small numbers of isolates identiﬁed by opportunistic sampling, like ret-
rospective testing of previously identiﬁed atypical MRSA isolates. It is
difﬁcult to understand how commonmecC MRSA truly is. The presence
of mecC MRSA has been reported in animals and humans from several
European countries, including Spain (Gomez et al., 2014), England
(Paterson et al., 2013), Denmark (Petersen et al., 2013), France
(Haenni et al., 2014), Germany (Cuny et al., 2011), Sweden
(Unnerstad et al., 2013), Belgium (Vandendriessche et al., 2013),
Austria (Loncaric et al., 2014), and Finland (Gindonis et al., 2013) show-
ing awide geographical spread of these isolates. Several studies demon-
strated thatmecCMRSA is frequent in dairy cattle, suggesting that cows
might provide a reservoir of infection. Gomez et al. (2015) foundmecC
MRSA in red deer in Southern Spain, suggesting that red deer could be
acting asmecC MRSA hosts and could share these gene with other ani-
mals, such as small mammals when they coexist in the same habitat.
In Sweden, Unnerstad et al. (2013) reported mecC MRSA in domestic
animals suggesting them as potential reservoirs with associated risks
to humans. Loncaric et al. (2014), in Austria, reportedmecC MRSA in 2
bovine and 1 ovine from an organic farm. When wildlife and livestock
share the same habitat, interspecies transmission can occur, either direct-
ly or indirectly.mecCMRSAwas also found in urban wastewater, indicat-
ing that this gene can be expanding to new areas (Porrero et al., 2014).
Even though the origin of mecC MRSA is unclear, there is evidence that
contact with animals poses a zoonotic risk and that mecC MRSA can be
transmitted between species (Paterson et al., 2014).
In humans,mecC genehas beenpredominantly described in skin and
soft tissue infections, including fatal bacteremia. Garcia-Garrote et al.
(2014) reported the ﬁrst mecC MRSA human case in Spain, a patient
with sepsiswhodied in the emergency department, highlighting the ur-
gency of the implementation of testingmethods in routine laboratory in
order to rapidly detect and treat these emerging strains. The clinical im-
pact of mecC MRSA is not fully determined. Isolates with MIC values to
oxacillin/cefoxitin around the breakpoints should be regarded as sus-
pect mecC MRSA demanding a respective mecC targeting assay
(Becker et al., 2014).
Due to the signiﬁcant heterogeneity between studies (see Cochran's
Q and I2 observed results in Fig. 2), random-effects model for meta-
analysiswasused in this study. The estimatedprevalence in human sub-
group is 0.004% (95% CI = 0.002–0.007), and the estimated prevalence
of animal subgroup is 0.098% (95% CI = 0.033–0.174). The overall esti-
mated prevalence is 0.009% (95% CI = 0.005–0.013).
The evaluation of mecC prevalence in humans and animals, to help
monitoring the epidemiology of this emerging form of MRSA, is funda-
mental to stimulate the development of procedures that allow the cor-
rect diagnostic of mecC gene leading to adequate treatment decisions
Fig. 2. Prevalence ofmecC MRSA among studies included in meta-analysis.
Fig. 3. Funnel plot analysis.
Table 2
Sensitivity analysis.
Excluded study Pooled prevalence LCI 95% HCI 95% I2
Paterson et al. (2013) 0.010 0.006 0.015 93.51
Ganesan et al. (2013) 0.010 0.006 0.015 93.48
Petersen et al. (2013) 0.011 0.006 0.018 91.83
Stegger et al. (2012) 0.008 0.004 0.012 92.93
Cuny et al. (2011) 0.011 0.006 0.017 92.32
Schaumburg et al. (2012) 0.010 0.006 0.015 93.24
Schlotter et al. (2014) 0.007 0.004 0.010 91.77
Vandendriessche et al. (2013) 0.009 0.005 0.014 93.47
Vandendriessche et al. (2013) 0.009 0.005 0.014 93.52
Deplano et al. (2014) 0.010 0.006 0.016 93.41
Garcia-Garrote et al. (2014) 0.010 0.006 0.015 92.77
Gomez et al (2015) 0.009 0.005 0.013 93.51
Porrero et al (2014) 0.009 0.005 0.013 93.45
Gomez et al. (2015) 0.009 0.005 0.013 93.38
Gomez et al (2015) 0.007 0.004 0.011 92.35
Ariza-Miguel et al (2014) 0.010 0.006 0.014 93.51
van Duijkeren et al. (2014) 0.009 0.005 0.014 93.52
Basset et al. (2013) 0.010 0.006 0.015 93.45
Kerschner et al. (2014) 0.008 0.005 0.013 93.35
Gindonis et al (2013) 0.009 0.005 0.014 93.50
Unnerstad et al. (2013) 0.009 0.006 0.014 93.50
Aqel et al. (2014) 0.009 0.005 0.014 93.52
Loncaric et al. (2014) 0.008 0.005 0.013 93.28
Haenni et al. (2014) 0.008 0.005 0.013 93.19
Dermota et al. (2015) 0.009 0.005 0.013 93.38
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when managing MRSA infections. This study shows that the overall es-
timated prevalence ofmecC MRSA is still very low.
To evaluate the robustness of the estimate, 5 studies with highest
prevalence were excluded (Gomez et al., 2014, 2015; Haenni et al.,
2014; Loncaric et al., 2014; Schlotter et al., 2014). The overall prevalence
presents signiﬁcant differences from the obtained when all the studies
were included in meta-analysis, and the estimated prevalence is
0.005. In these excluded studies, the authors used small samples of
MRSA to screen mecC gene resulting in a high prevalence of this gene
comparing with the other studies included in meta-analysis.
Sensitivity analysis by excluding 1 study at each turn and pooling re-
sults from the remainder further conﬁrmed the robustness of our ﬁndings.
5. Conclusion
The discovery of themecC genemay represent a public health threat
since phenotypic and genotypic tests seem to be insufﬁcient to detect
this new resistance mechanism. The pool of results collected for this
analysis indicates that it is important to study the prevalence of this
gene in healthcare units to understand its dissemination and evolution
over time and mainly to look for alternative treatments for infections
caused byMRSA harboring this new gene. In this study, the overall esti-
mated prevalence of mecC gene is 0.009% (95% CI = 0.005–0.013). Al-
though the prevalence of mecC gene is extremely rare and only
reported in European countries, diagnostic protocols, whether for clini-
cal or epidemiological purposes, should consider the ramiﬁcations of
not detecting S. aureus strains that carry this newmecA homolog.
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Objectives: Vancomycin is currently the primary option treatment for methicillin-resistant Staphylo-
coccus aureus (MRSA). However, an increasing number of MRSA isolates with high MICs, within the
susceptible range (vancomycin MIC creep), are being reported worldwide. Resorting to a meta-analysis
approach, this study aims to assess the evidence of vancomycin MIC creep.
Methods: We searched for studies in the PubMed database. The inclusion criteria for study eligibility
included the possibility of retrieving the reported data values of vancomycin MIC and information
concerning the applied MIC methodology.
Results: The mean values of vancomycin MICs, of all 29 234 S. aureus isolates reported in the 55 studies
included in the meta-analysis, were 1.23 mg/L (95% CI 1.13e1.33) and 1.20 mg/L (95% CI 1.13e1.28)
determined by Etest and broth microdilution method, respectively. No signiﬁcant differences were
observed between these two methodologies. We found negative correlation between pooled mean/
pooled proportion and time strata.
Conclusions: We have found no evidence of the MIC creep phenomenon. R. Diaz, Clin Microbiol Infect
2017;▪:1
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Staphylococcus aureus is one of the most common pathogens
causing severe infections [1]. Infections caused by methicillin-
resistant Staphylococcus aureus (MRSA) are associated with
increased morbidity, longer antibiotic therapy, higher healthcare
costs, prolonged hospitalization and increased risk of death [2].
The ﬁrst option for the treatment of invasive MRSA infections is
the glycopeptide vancomycin, which continues to be the reference
standard approach in this context [3]. The use of vancomycin has
been increasing since the mid-1980s, resulting in the emergence of
MRSA with reduced susceptibility to vancomycin [2]. Recently, a
phenomenon of gradual increase in the value of glycopeptide MIC
for S. aureus was observed and reported in the literature as MIC
creep [4]. The publications related to MIC creep included studies
that report increases in the mean vancomycin MIC as well as
studies that did not conﬁrm these ﬁndings in MRSA [3,5,6]. In this
context, and as a result of the reported vancomycin therapy failure
in patients with S. aureus infections with a MIC !4 mg/L, the CLSI
reduced vancomycin breakpoints from "4 mg/L to "2 mg/L, for
susceptible S. aureus, and from !32 mg/L to !16 mg/L for resistant
S. aureus. These changes aimed to increase the sensitivity of the
detection of non-susceptible isolates [3,7]. The apparent increase in
vancomycin MIC among MRSA, observed in recent years, can
represent the ﬁrst step towards the appearance of fully resistant
isolates. Patients infectedwithMRSA isolates that exhibit MIC creep
might experience poorer clinical outcomes, including delayed
treatment response, increased mortality, increased rate of relapse,
extended hospitalization or overall increased cost of hospitalization
[2,7,8].
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Soriano et al. showed that mortality associated with MRSA
bacteraemia was signiﬁcantly higher when the empirical antibiotic
was inappropriate and when vancomycin was empirically used for
the treatment of infection with strains with high vancomycin MIC
(>1 mg/L) [9].
The MIC creep phenomenon may be inﬂuenced by the type of
microbiological susceptibility test used (Etest, broth microdilution
(BMD) or automated system) [2,10], type of S. aureus strain or type
of patient population evaluated [2]. The reference standard for
measuring MIC remains BMD [11].
In the literature it is possible to ﬁnd studies that show vanco-
mycin MIC creep by using BMD [12] and Etest methods [13], and
studies that found no vancomycin MIC creep when using the same
methods [12e14]. Such inconsistent information about the MIC
creep phenomenon and conﬂicting results have been noted in cases
in which MIC creep could not be detected. Hence, in an attempt to
clarify these inconsistencies and conﬂicting results, this study aims
to assess the evidence of MIC creep, using a meta-analysis, high-
lighting the type of applied MIC methodologies.
Materials and methods
Search strategy and selection criteria
The studies to be included in the meta-analysis approach were
retrieved from the PubMed database. The search query was
‘methicillin-resistant staphylococcus aureus’ OR ‘Methicillin-Resis-
tant Staphylococcus aureus‘[Mesh]’’ OR ‘MRSA’ AND ‘vancomycin’
OR ‘vancomycin‘[Mesh]’’ AND ‘minimal inhibitory concentration’
OR ‘MIC’ OR ‘MIC creep’ OR ‘reduced vancomycin susceptibility’ OR
‘vancomycin susceptibility trends’.
The abstracts of the collected articles were reviewed and a study
was considered to be eligible for inclusion if it included values of
vancomycin MIC and details of the applied MIC methodologies.
SelectedMICmethodologies were: microdilution (BMD), Etest, agar
diffusion and automated systems.
Data analysis
Data extraction
After the analysis of both titles and abstracts, the selected
studies were independently assessed and analysed by three authors
(R. Diaz, V. Afreixo and C. Rodrigues).
Data extracted from the identiﬁed studies included MIC van-
comycin information applied methodology, number of studied
isolates, source of isolate, year of study completion and country (see
Supplementary material, Data S1).
Data uniformization
In the cases of the studies that only reported median, minimum
(min) and maximum (max) values, it was assumed that the sym-
metry and mean values were estimated from the median. To esti-
mate the standard deviation (SD), the authors assumed uniformity
with a variable distribution and the SD¼ (maxemin)/√12. To
complete the table of statistics (mean, SD, min), all MIC values "0.5
were converted to 0.5.
In studies in which the results were grouped by periods of
#2 years, the counts were divided in a uniform manner by periods
under review.
To create groups with similar numbers of effects, the following
stratiﬁcation of study years under analysis was selected, resulting
in seven time strata: <2000; 2000e2001; 2002e2003;
2004e2005; 2006e2007; 2008e2009 and #2010. The time strata
<2000 and #2010 are created to reach a more uniform number of
studies in each stratum. To aggregate results from different years,
from the same study, weighted averages, combined variances and
accumulated frequencies were used.
Some criteria were deﬁned before starting the meta-analysis on
the 53 included studies: (a) in studies that presented data of frozen
isolates and data of ‘at time’ isolates, data of ‘frozen isolates’ were
used because most of the studies determined MICs in ‘frozen iso-
lates’ [6]; (b) in the case of studies with data of automatedmethods,
only data of the VITEK method were considered as it is the only
method common to all studies [15]; (c) studies of the same author
and year were identiﬁed with A and B [15e18]; (d) studies that
included different cities were identiﬁed with A and B [3]; (e) data
presented in more than one study of the same author were
excluded [17,18].
Statistical analysis
Homogeneity among studies was computed using the Cochran's
Q statistic and the I2 statistic. A signiﬁcant Q statistic suggests that
the distribution of effect sizes around the mean is greater than it
would be predicted from sampling error alone. On the other hand,
I2 provides an estimate of the proportion of the variance in the
aggregate effect size that is attributable to study heterogeneity,
with values of 0.25, 0.50 and 0.75 indicating low, moderate and
high degrees of heterogeneity.
To perform a secondary study, a subgroup analysis was carried
out with the mean of vancomycin MIC and the proportion of
S. aureus isolates with vancomycin MIC #2 mg/L in four subgroups
of regions: (a) Europe, (b) USA, (c) Asia and (d) others. Due to the
signiﬁcant heterogeneity between the studies, the pooled preva-
lence for each group was estimated using the random-effects
model.
To compare the pooled effect size in different groups (sub-
groups) the Z-test was used and for simultaneous statistical tests
the Sidak correction was applied [19].
METAXL 1.0, a tool for meta-analysis in MICROSOFT EXCEL, was used
to pool individual prevalence from each study.
Results
Literature search, based on the keywords described in the Ma-
terials and methods section, identiﬁed 980 studies (Fig. 1). After
title and abstract analysis, 880 were excluded and 100 full-text
articles were reviewed [1,3e6,8,9,11e18,20e104]. Of these, 55
studies were included in the meta-analysis (see Supplementary
material, Table S1), 45 were excluded for the following reasons:
data were included in another study of the same author (two
studies) [87], no MIC data were available (35 studies)
[21,26,27,30,31,33,35,37,38,41,44,47,48,53,54,59,64,69,70,78,80,82,
83,89,90,92,94,95,97,101,102,104], full-text versions were unavai-
lable (two studies) [75,77], different guidelines were used (two
studies) [47,103] and meta-analysis and review articles (four
studies) [8,46,57,93].
Considering all studies included in the pool (n ¼ 55), the mean
vancomycin MIC was 1.20 mg/L (95% CI 1.13e1.28), 1.23 mg/L (95%
CI 1.13e1.33) and 1.19 mg/L (95% CI 1.07e1.30), when determined
by the BMD method, Etest method and agar method, respectively.
The pooled mean of vancomycin MIC determined resorting to the
automatedmethod was lower compared with values obtained with
the other methods (1.10 mg/L) (Table 1). The differences between
studied MIC methodologies were not statistically signiﬁcant (p
>0.05, Z-test with Sidak correction for multiple comparisons).
To evaluate the robustness of our uniformization, sensitivity
analysis was conducted. In four studies themean valuewas inferred
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through the median [3,24,40,79], excluding these studies the
overall results do not present signiﬁcant differences, the overall
results are similar with negative correlation values, !0.68
and !0.64 for Etest and BMD, respectively.
Considering the pooledmean of vancomycinMIC over each time
stratum represented in Figs. 2 and 3, studies before the year 2000
showed the highest vancomycin MICs pooled values. After the year
2007 vancomycin MIC showed a slight decrease (negative
Spearman correlation between time strata and pooled mean)
(Table 2). In general, the results were similar for BMD (Fig. 2) and
Etest (Fig. 3) methods.
The CLSI guidelines consider S. aureus to be susceptible to van-
comycin for MICs <2 mg/L [105]. Considering this guideline, the
pooled proportion of MRSA isolates with vancomycin MIC "2 mg/L
was evaluated and shown to be low, between 14% and 18%, for all
the applied testing methods (Table 2).
Fig. 1. Results of literature search.
Table 1
Statistical results of pooled mean vancomycin MICs determined resorting to different MIC testing methodologies
MIC testing
methodologies
Pooled
mean
95% CI Spearman
correlationa
I2 Number of independent
studies
Number
of samples
Lower bound Upper bound
MRSA BMD 1.20 1.13 1.28 !0.82 98.69 16 8328
Etest 1.23 1.13 1.33 !0.57 99.61 27 7426
Agar 1.19 1.07 1.30 d 97.64 6 1626
Automated system 1.10 0.83 1.38 d 99.24 7 1555
a Spearman correlation: correlation between time strata and pooled mean.
Fig. 2. Pooled mean of vancomycin MIC determined by the broth microdilution method over time. The bubble size represents the meta-analysis sub-group weight.
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The analysis of the distribution of MRSA isolates with vanco-
mycin MIC !2 mg/L showed a decrease over time, with either BMD
(Fig. 4) or Etest (Fig. 5) methods. For the Etest method, a slight
oscillation was observed between 2000 and 2007, followed by a
tendency to decrease after 2007 (negative Spearman correlation)
(Table 2).
Regarding the analysis of the pooled mean of vancomycin MIC
by region, (Europe, USA, Asia and other countries), in Europe the
pooled mean of vancomycin MIC determined with the BMD
method was 1.12 mg/L (see Supplementary material, Fig. S1) and
with the Etest method was 1.13 mg/L (see Supplementary material,
Fig. S2). In Asia, the pooled mean of vancomycin determined with
the BMD method was 1.17 mg/L (see Supplementary material,
Fig. S1) and with the Etest method was 0.98 mg/L (see
Supplementary material, Fig. S2). Regarding the USA, these values
were slightly increased, with values of 1.37 mg/L and 1.53 mg/L for
the BMD method and Etest method, respectively (see
Supplementary material, Figs. S1 and S2).
By region, the proportion ofMRSA isolateswith vancomycinMIC
!2 mg/L was 17% in Europe, 26% in the USA and 18% in Asia, for the
BMDmethod. For the Etest method the proportion of MRSA isolates
was 11% in Europe, 27% in USA and 3% in Asia (Table 3).
Discussion
This study is the ﬁrst meta-analysis with a worldwide
perspective that evaluates the trends of vancomycin MIC over time,
determined by different MIC methodologies, and no statistically
signiﬁcant evidence of the MIC creep phenomenon was detected.
The standard for measuring MIC remains BMD; but this is a la-
bour intensive technique and many laboratories use the Etest
method as an alternative. These two methods were selected for
evaluation in more detail in this work.
The results of the pooled means of vancomycin MICs for all
MRSA isolates reportedwith BMD and Etestmethodswere 1.20mg/
L and 1.23 mg/L, respectively, and no signiﬁcant differences were
Fig. 3. Pooled mean vancomycin MIC determined by the Etest method over time. The bubble size represents the meta-analysis sub-group weight.
Table 2
Pooled proportion of the Staphylococcus aureus isolates with vancomycin MIC !2 mg/L determined using to different MIC testing methodologies
MIC testing
methodologies
Pooled
proportion
95% CI Spearman
correlationa
I2 Number of independent
studies
Number of
samples
Lower bound Upper bound
MRSA Broth microdilution 0.18 0.12 0.25 "0.89 98.48 17 10 350
Etest 0.14 0.10 0.19 "0.64 96.86 27 7389
Agar 0.15 0.04 0.30 d 98.32 7 2016
Automated system 0.18 0.05 0.36 d 97.99 6 1406
a Spearman correlation: correlation between time strata and pooled proportion.
Fig. 4. Pooled proportion of methicillin-resistant Staphylococcus aureus isolates with vancomycin MIC !2 mg/L determined with the broth microdilution method. The bubble size
represents the meta-analysis sub-group weight.
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observed between these two methods. The number of strains
studied with the agar method was very low when compared with
other methodologies; however, the pooled mean of vancomycin
MIC for this method (1.19 mg/L) was not signiﬁcantly different from
the others. Based on clinical laboratory practice, as expected, the
pooled mean of vancomycin MIC determined with an automated
method (1.10 mg/L) was lower than those determined with other
methodologies studied. This result is consistent with the study of
Tomczak et al., which reports differences between vancomycin MIC
assayed with an automated method and Etest method [4].
When considering pooled mean of vancomycin MIC over time,
studies published before the year 2000 exhibited the highest van-
comycin MICs and after 2007 vancomycin MICs showed a slight
decrease. Results were similar for BMD and Etest methods. These
ﬁndings are consistent with the results reported previously by
other authors that did not ﬁnd trends in vancomycin MIC. Some
examples are the SENTRY Antimicrobial Surveillance Program
database, where, between 1998 and 2003, 35 458 S. aureus isolates
where studied [106], a multicentre study of nine USmedical centres
where 1800MRSA samples where studied, between 1999 and 2006
[107], and a survey from Spain that, between 2002 and 2006,
evaluated 3141 S. aureus isolates [12].
Considering the upper vancomycin breakpoint for susceptible
S. aureus, a subgroup analysis was carried with the proportion of
S. aureus isolates with vancomycin MIC !2 mg/L; comparing the
two main testing methods under analysis the MRSA pooled pro-
portion was very low (11%e27%). Additionally, over time strata,
both BMD and Etest methods showed a decrease in vancomycin
MIC, strengthening the observation of no evidence of MIC creep, as
supported by the Spearman's correlation coefﬁcient (Table 2). The
decrease trends observed in both analyses for the last time-strata,
can suggest a positive impact of implementation of more rigorous
clinical strategies for the management of MRSA infection.
This study also enabled the evaluation of the pooled mean of
vancomycin MIC by region (see Supplementary material, Figs. S1
and S2). The results showed a lower pooled mean of vancomycin
MIC in Europe and a slightly higher pooled mean of vancomycin
MIC in the USA. It is expected that an increased value of vancomycin
MIC is related to the overall prevalence of MRSA, with a higher
value of vancomycin MIC linked to higher MRSA prevalence. When
correlating our results with the overall prevalence of countries
included in the meta-analysis, this can be found in the USA and
China where the overall prevalence of MRSA is 55.9% [56] in the
USA (with a pooled mean of vancomycin 1.12 mg/L and 1.13 mg/L,
determined with BMD and Etest, respectively) and 46.8% in China
[56] (with a pooled mean of vancomycin 1.17 mg/L for BMD and
0.98 mg/L for Etest).
One of the problems of combining data from multiple centres is
that it can obscure trends thatmay exist within a given institution or
country, because of differences in patient populations and drug-
usage patterns. One possible limitation of our study is the inclusion
of large multicentre studies, but the negative values obtained with
Spearman's correlation coefﬁcient even with inclusion of these
studies, substantiatenoevidenceof vancomycinMICcreepover time.
The present study did not detect an increase in vancomycin MIC,
suggesting that vancomycin continues to be the standard option in
treatment of MRSA infections when MIC is determined with Etest
or BMD methods and in institutions that continuously evaluate
their local susceptibility proﬁles. Future studies must focus on the
analysis of vancomycin MIC creep on a regional basis, tested at the
same locations and using the same methodologies.
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Fig. 5. Pooled proportion of methicillin-resistant Staphylococcus aureus isolates with vancomycin MIC !2 mg/L determined with the Etest method. The bubble size represents the
meta-analysis sub-group weight.
Table 3
Pooled proportion of the methicillin-resistant Staphylococcus aureus isolates with vancomycin MIC !2 mg/L, by region
MIC testing
methodologies
Region Pooled 95% CI I2 Number of independent
studies
Number of
samples
Lower bound Upper bound
Broth microdilution Europe 0.17 0.06 0.31 99.58 5 1585
USA 0.26 0.00 0.71 4 4518
Asia 0.18 0.00 0.44 4 3235
Other 0.10 0.00 0.42 2 435
Etest Europe 0.11 0.04 0.20 98.92 10 1730
USA 0.27 0.11 0.46 11 4578
Asia 0.03 0.00 0.09 5 987
Other 0.23 0.00 0.65 2 435
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A B S T R A C T
Objectives: Vancomycin is the primary treatment for methicillin-resistant Staphylococcus aureus (MRSA).
However, an increasing proportion of MRSA isolates with high minimum inhibitory concentrations
(MICs) within the susceptible range (vancomycin ‘MIC creep’) is being observed. The aim of this study was
to assess the vancomycin MIC distribution for S. aureus isolates over a period of 4 years in Centro
Hospitalar Baixo Vouga (Aveiro, Portugal) and to identify differences in vancomycin MIC determined by
different susceptibility testing methods.
Methods: For each S. aureus isolate, the vancomycin MIC was assayed by the VITEK12 automated system
and the broth microdilution testing method.
Results: The results showed signiﬁcant differences in vancomycin MIC by different methods (P = 0.021,
sign test) and did not suggest the presence of vancomycin MIC creep during the study period.
Conclusions: Vancomycin MIC creep is a regional problem, therefore it can only be assessed through the
evaluation of local susceptibility proﬁles, and antibiogram based on real MIC assay should be an essential
element in local MRSA infection clinical management.
© 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.
1. Introduction
Staphylococcus aureus is one of the most common pathogens
causing severe infections both in community and hospital settings.
Generally these infections are associated with increased morbidity,
longer antibiotic therapy, higher healthcare costs, prolonged
hospitalisation and increased risk of death [1]. The ﬁrst antibiotic
agent used for the treatment of invasive methicillin-resistant S.
aureus (MRSA) infections is the glycopeptide vancomycin, which
remains the gold-standard approach [2]. Utilisation of vancomycin
has been increasing since the mid-1980s, resulting in the
emergence of MRSA with reduced vancomycin susceptibility [1].
Recently, a phenomenon of gradual increase in glycopeptide
minimum inhibitory concentrations (MICs) for S. aureus has been
observed and is described in the literature as ‘MIC creep’ [3].
Patients with isolates exhibiting MIC creep have been
associated with poor clinical outcomes, including delayed re-
sponse, increased mortality, increased rate of relapse, prolonged
hospital stay and overall increased cost of hospitalisation [1,4,5].
Publications regarding MIC creep include studies that report an
increase in the mean vancomycin MIC as well as studies that do not
conﬁrm these ﬁndings in MRSA [2].
Combining data from multiple centres can obscure trends that
may exist within a given institution(s) or country as a result of
differences in patient populations and drug usage patterns.
Therefore, it is important to study vancomycin MIC creep as a
regional problem, and evaluation of local susceptibility proﬁles
should be essential in local MRSA infection clinical management
[6]. Owing to evidence of MIC creep in some regions, the aim of
this study was to assess the vancomycin MIC distribution for S.
aureus isolates over a period of 4 years in Centro Hospitalar Baixo
Vouga (CHBV) (Aveiro, Portugal). The study aimed to identify
trends and differences in vancomycin MICs determined by
different susceptibility testing methods. Detection of a tendency
for vancomycin MIC creep in MRSA strains in a particular
population should prompt regional health authorities to include
these data in future discussions regarding treatment protocols and
strategies.
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2. Materials and methods
2.1. Aims and study design
This study aimed to assess the possibility of vancomycin MIC
creep amongst S. aureus isolates from various clinical sources.
Second, it aimed to identify differences in vancomycin MIC
determined by different susceptibility testing methods. Vancomy-
cin susceptibility was comparatively evaluated by two testing
methods, namely the VITEK12 automated system (bioMérieux,
France) [7] and the broth microdilution (BMD) method [8].
2.2. Study population and data collection
A total of 101 clinical S. aureus isolates obtained between 2010
and 2013 from CHBV were analysed. Isolates were identiﬁed by
routine bacteriological procedures. Only one isolate per patient
was included. Isolates were collected from various clinical sources,
including respiratory tract (n = 36), blood (n = 22), wounds (n = 38),
urine (n = 2) and others (n = 3). These isolates were included in the
isolates that were sent to the SENTRY antimicrobial surveillance
programme. Patient demographic characteristics and clinical data
were obtained from the medical records. From the 101 isolates,
only 95 had data available for the two methodologies.
2.3. Laboratory methods
For each S. aureus isolate, the vancomycin MIC was assayed for
methicillin-susceptible S. aureus (MSSA) and MRSA by the two
testing methods. The susceptible breakpoint for vancomycin was
2 mg/L [9]. Susceptibility testing was performed using the VITEK12
instrument with commercially available Staphylococcus cards (GP,
AST619; bioMérieux) and the same isolates were directed to
SENTRY for the evaluation of vancomycin MICs by the BMD
method.
2.4. Statistical analysis
Vancomycin MICs were dichotomised (MIC ! 0.5 mg/L and
MIC = 1 mg/L). The association between categorical variables was
determined by x2 test. Quantitative variables were compared using
the non-parametric paired-sign test, Kruskal–Wallis test or Mann–
Whitney test. The x2 test was used for MIC trends over time.
Comparison between the two methods was performed by means of
the Spearman’s non-parametric correlation.
All statistical analyses were performed using IBM SPSS Statistics
v.22.0 (IBM Corp., Armonk, NY), and tests with a P-value of <0.05
were considered statistically signiﬁcant.
3. Results
A total of 101 S. aureus isolates were analysed during the study
period. The majority of isolates were collected from the respiratory
tract and wounds. The studied groups were homogeneous and
comparable. The demographic and clinical characteristics of the
patients are summarised in Table 1. The main cause of infection
was MRSA, the leading cause of hospitalisation was tract
respiratory disease, and the two main co-morbidities were arterial
hypertension and diabetes.
Table 2 shows a comparison of the clinical presentation data
and outcomes between the vancomycin MIC ! 0.5 mg/L and
MIC = 1 mg/L groups. No signiﬁcant differences were found in in-
Table 1
Demographic characteristics, clinical presentation and clinical outcomes of 101 patients from Centro Hospitalar Baixo Vouga (Aveiro, Portugal) with Staphylococcus aureus
infections between 2010–2013.
2010 (n = 23) 2011 (n = 31) 2012 (n = 24) 2013 (n = 23) P-value
Age (years) (mean " S.D.) 73 " 18 70 " 19 73 " 16 72 " 10 0.676
Male sex [n (%)] 13 (56.5) 18 (58.1) 15 (62.5) 14 (60.9) 0.975
Cause of hospitalisation (n)
Anaemia 0 1 0 0 0.516
Diabetes 1 1 0 0 0.602
Cardiovascular disease 3 5 0 5 0.142
Respiratory disease 13 6 10 8 0.182
Genitourinary disease 2 2 2 0 0.567
Gastrointestinal tract disease 0 4 4 2 0.250
Systemic infection 3 0 2 1 0.223
Osteoarticular infection 1 4 2 1 0.601
Central nervous system infection 0 1 0 1 0.602
Neurological disease 0 3 0 1 0.203
Other 0 4 4 4 –
Co-morbidities (n)
Diabetes 8 10 8 7 0.991
Cancer 2 1 1 1 0.818
Anaemia 1 5 1 1 0.247
Heart disease 4 7 4 8 0.428
Alcoholism 0 1 3 0 0.088
Neurological disease 7 4 5 5 0.478
Kidney failure 7 6 9 2 0.099
Respiratory disease 3 6 4 0 0.182
Hepatitis 0 1 0 0 0.516
Arterial hypertension 10 9 9 11 0.519
Osteoarticular system disease 1 0 2 1 0.475
Skin and soft-tissue infection 9 1 2 1 0.000
Vancomycin BMD MIC ! 0.5 mg/L (n) 14 13 12 12 0.403
In-hospital mortality (n) 7 3 6 6 0.254
MRSA (n)a 19 26 22 21 0.68
MSSA (n)a 4 6 3 2 0.704
S.D., standard deviation; BMD, broth microdilution; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.
a Two patients had both MRSA and MSSA isolates.
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hospital mortality rate (P = 0.562) amongst patients harbouring
isolates with isolates with different MICs. Infection with MSSA was
strongly associated (P = 0.022) with higher MICs (1 mg/L).
All of the studied S. aureus isolates were susceptible to
vancomycin, exhibiting MICs below the current Clinical and
Laboratory Standards Institute (CLSI) breakpoint (<2 mg/L) [9].
A signiﬁcant association between MICs using the two methods
and the year (P = 0.006, x2 test) was obtained. In addition,
evaluation of vancomycin MICs by method showed signiﬁcant
differences for the same isolate (P = 0.021, sign test).
Correlations between MIC methods results and year were
evaluated. Spearman’s correlation coefﬁcient between year and
BMD was !0.006 (P = 0.957) and between year and automated
system analysis was 0.360 (P = 0.000), supporting the results in
Fig. 1.
Automated system vancomycin MICs were also signiﬁcantly
lower (71%, MIC " 0.5 mg/L; 29% MIC 1 = mg/L) than those found by
BMD analysis (54%, MIC " 0.5 mg/L; 46% MIC = 1 mg/L) (P = 0.007,
sign test).
4. Discussion
Vancomycin MIC creep in S. aureus is a phenomenon whereby
isolates with higher vancomycin MICs are becoming more
common, although MICs remain within the susceptible range of
the drug [10]. Studies reporting changes over time in MRSA isolates
have revealed conﬂicting results, with MIC creep noted in some
populations but not in others [1]. This study aimed to analyse
trends in vancomycin MICs obtained using an automated system
and BMD between 2010 and 2013 for S. aureus isolates collected
from various clinical sources. For BMD analysis, no signiﬁcant
increase was found, a result consistent with others studies, e.g. the
SENTRY database in which between 1998–2003 a total of 35 458 S.
aureus isolates were studied [11], a multicentre study of nine US
medical centres with 1800 MRSA samples between 1999–2006
[12] and a survey from Spain between 2002–2006 with 3141 S.
aureus isolates [13].
On the other hand, increasing vancomycin MICs were reported
in a single centre in France that studied 1445 MRSA between 1983–
2002 [1,13], a multiple single-centre study in the USA that studied
662 MRSA between 1999–2006 [14,15] and a study in Hong Kong
that analysed 247 MRSA between 1997–2008 [16].
Noteworthy, in a study that examined 287 MRSA isolates from
blood cultures collected at several hospitals in two German cities
between 2004–2009, an increase in vancomycin MIC was detected
in only one city, suggesting a regional problem and highlighting the
importance of regional studies as well as the need to empower
regional health centres to monitor their local status [2].
Nevertheless, the reason for the detection of the MIC creep
phenomenon in some centres but not in all has not yet been
completely elucidated. The high heterogeneity of the studies make
a direct comparison difﬁcult. Indeed, studies differ in the analysed
period, type of isolates, clinical source of the isolates as well the
methods used for susceptibility testing [2,5]. The reports reveal
that there are studies which did not ﬁnd vancomycin MIC creep
using the BMD method [17] or Etest [18] and others that found
changes using the same methodologies [14,15,17].
Reports suggest that the Etest method is more sensitive in
detecting small vancomycin MIC changes than the BMD and the
automated system [1,2]. The reliability of the automated method
applied to measure the MIC of glycopeptides for S. aureus must be
treated with caution. In the results of this work, considerable
differences between methods were observed. Automated analysis
shows some tendency for MIC creep, whilst in BMD the gradual
increase in MIC does not show any tendency. The automated
system provided MICs of vancomycin "0.5 mg/L in 71% of cases and
1 mg/L in 29% of cases. On the other hand, with the BMD an MIC of
0.5 mg/L was obtained in 54% of cases and 1 mg/L in 46% of cases.
Table 2
Comparison of clinical presentation data and outcomes between vancomycin
MIC " 0.5 mg/L and MIC = 1.0 mg/L groups by the broth microdilution (BMD)
method (n = 95).
MIC " 0.5 mg/L MIC = 1.0 mg/L P-value
No. of patients 51 44
Age (years) (mean # S.D.) 72 # 14 70 # 18 0.964
Male sex (n) 32 24 0.418
Cause of hospitalisation (n)
Anaemia 0 1 0.279
Diabetes 2 0 0.184
Cardiovascular disease 4 9 0.075
Respiratory disease 21 13 0.238
Genitourinary disease 5 1 0.132
Gastrointestinal tract disease 6 4 0.672
Systemic infection 5 1 0.132
Osteoarticular infection 3 5 0.337
Central nervous system infection 1 1 0.916
Neurological disease 3 1 0.382
Other 1 8
Co-morbidities (n)
Diabetes 17 12 0.522
Cancer 4 1 0.225
Anaemia 4 4 0.827
Heart disease 11 11 0.693
Alcoholism 0 3 0.058
Neurological disease 10 11 0.528
Kidney failure 15 5 0.031
Respiratory disease 9 4 0.226
Hepatitis 0 1 0.279
Arterial hypertension 22 15 0.367
Osteoarticular system disease 2 1 0.647
Skin and soft-tissue infection 2 1 0.990
In-hospital mortality (n) 13 9 0.562
MRSA (n)a 47 35 0.075
MSSA (n)a 4 11 0.022
MIC, minimum inhibitory concentration; S.D., standard deviation; MRSA, methicil-
lin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.
a Two patients had both MRSA and MSSA isolates.
Fig. 1. Mean vancomycin minimum inhibitory concentrations (MICs) between 2010
and 2013 analysed by the VITEK12 automated system (- - -) and the broth
microdilution (BMD) method (—).
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These results show that vancomycin MICs from the automated
method were also signiﬁcantly lower than those by BMD. Owing to
these signiﬁcant differences in the results obtained by both
methods as well as according to reports in the literature showing
that there is a higher probability of clinical success when the MIC of
vancomycin does not exceed a value of 1.0 mg/L, it is important to
underline the fact that the real MIC assayed by means of Etest or
BMD is more useful than that provided by the automated method
[3,19]. These ﬁndings are consistent with the results from the study
by Tomczak et al. that compared the MIC obtained with the
automated method and Etest for S. aureus strains [3].
The results presented here have some limitations. First, this was
a retrospective single-centre study with possible sample selection
bias. In addition, longer periods are needed for a broad statement
about trends. Nevertheless, this is the ﬁrst study in Aveiro and the
second in Portugal, giving relevance to this study. Silvestre et al.
evaluated the presence of vancomycin MIC creep in 93 MRSA from
2007–2009 in a hospital in Lisbon (Portugal) and did not ﬁnd data
compatible with the presence of vancomycin MIC creep [20].
Since this appears to be a regional problem, we suggest that all
hospitals should monitor their local status of vancomycin MICs in
order to evaluate the presence of trends and to ensure the
effectiveness of vancomycin therapy. Considering our results, it is
important in our hospital to evaluate vancomycin MICs during the
next years in order to observe whether differences between two
methodologies continue and whether the automated method
continues to shows some tendency for MIC creep.
5. Conclusion
This study showed signiﬁcant differences in vancomycin MIC
with different methods and no evidence of vancomycin MIC creep.
The relevance of vancomycin creep for individual clinicians,
pharmacists and microbiologists can only be assessed through
the evaluation of local susceptibility proﬁles and not from
published observations of other researchers. The antibiogram
based on the real MIC assay should be an essential element when
vancomycin therapy is instituted in the clinical management of
MRSA infections, avoiding whenever possible the use of vancomy-
cin MIC based on automated methods.
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Part	III. Discussion	and	conclusions	
	Regardless	 the	 big	 number	 of	 antistaphylococcal	 antibiotics	 that	 are	 available,	the	S.aureus	ability	to	adapt	makes	it	one	of	the	principal	causes	of	morbidity	or	even	mortality	 (2)	This	microorganism	 is	 responsible	both	 for	nosocomial	 and	community	 infections	 (13).	Vancomycin	 is	 the	 “gold	standard”	 for	 treatment	of	invasive	MRSA	 infections	 (4).	 The	work	 developed	 during	 the	 development	 of	this	 thesis	 underline	 two	 points	 that	 can	 influence	 the	 treatment	 response	 in	case	of	S.aureus	 infections:	the	possible	presence	of	mecC	gene	and	vancomycin	MIC	increase.		In	2011,	mecC	gene	was	 found	 in	MRSA	 isolates	 from	humans	and	animals	(9).	This	 gene	 shares	 69%	 nucleotide	 homology	 with	 mecA	 (9).	 This	 discovery	created	theories	about	the	origin,	epidemiology	and	impact	of	these	isolates	and	the	prevalence	of	mecC	gene	became	an	important	public	health	issue.	The	study	entitled	 “Methicillin-resistant	 Staphylococcus	 aureus	 carrying	 the	 new	 mecC	gene—a	meta-analysis”	aimed	to	apply	meta-analysis	techniques	to	perform	an	improved	evaluation	of	the	available	data	on	overall	prevalence	of	mecCMRSA	in	humans	and	animals.	With	 this	 study	we	 found	an	estimated	prevalence	 in	 the	human	subgroup	of	0.004	(95%	[CI]	=	0.002–0.007),	an	estimated	prevalence	in	the	animal	subgroup	of	0.10	(95%	[CI]	=	0.033–0.174)	and	the	overall	estimated	prevalence	of	0.009	(95%	[CI]	=	0.005–0.013)(92).	Several	studies	demonstrated	that	mecCMRSA	is	frequent	in	dairy	cattle,	suggesting	that	cows	might	provide	a	reservoir	 of	 infection	 (93),	 in	 fact,	 our	 results	 showed	 higher	 prevalence	 in	animals	subgroup	when	compared	to	the	human	subgroup	and	with	dairy	cattle	as	 the	most	 frequent	 subgroup	with	 this	 infection.	 In	 humans,	mecC	 gene	 has	been	predominantly	described	 in	skin	and	soft	 tissue	 infections,	 including	 fatal	bacteremia	(94).	mecCMRSA	was	also	found	in	urban	wastewater,	indicating	that	
mecC	gene	can	expand	to	new	areas	(95).	Even	though	the	origin	of	mecCMRSA	is	unclear,	 there	 is	 proof	 that	 animal	 contact	 poses	 a	 zoonotic	 risk	 and	 that	
mecCMRSA	can	be	transmitted	between	different	species	(96).		The	 importance	 of	 monitor	 the	 presence	 of	mecC	 in	 S.aureus	 isolates	 in	 both,	humans	and	animals,	lead	to	an	update	to	the	results	of	our	previous	published	
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meta-analysis	 and	a	new	research	was	performed	 to	 include	 recent	 reports	on	
mecC	prevalence.	This	update,	replicates	literature	review	method	reported	but	for	 articles	 published	 between	 April	 2015	 and	 August	 2017.	 Ten	 new	 studies	were	selected	based	on	 the	same	 inclusion	and	exclusion	criteria	 (66,	97-105).	These	 studies	 were	 added	 to	 the	 studies	 already	 included	 in	 the	 first	 meta-analysis.	The	estimated	prevalence	in	the	human	subgroup	was	now	0,004	(95%	[CI]	 =	 0.002–0.007),	 the	 estimated	 prevalence	 in	 the	 animal	 subgroup	 0,118	(95%	[CI]	=	0.063–0.179)	and	the	overall	prevalence	0.018	(95%	[CI]	=	0.012–0.024).	The	overall	prevalence	increased	from	0.009	(95%	[CI]	=	0.005–0.013)	to	0,018	(95%	[CI]	=	0.012–0.024).	Although	the	estimated	prevalence	has	doubled,	the	 updated	 results	 did	 not	 show	 significant	 differences,	 since	 the	 95%	 CI	overlaps	the	previous	one.	These	updated	results	showed	a	slightly	increased	in	two	years	and	it	 is	expect	that	 a	 gradual	 increase	 over	 time	 will	 occur,	 namely	 in	 the	 animal	 subgroup,	increasing	 the	 zoonotic	 risk	 and	 highlighting	 the	 importance	 of	 monitoring	
S.aureus	 strains	carrying	mecC.	This	updated	 literature	search	also	noticed	that	
mecC	 was	 described	 in	 three	 new	 countries,	 Italy	 (66),	 Australia	 (102)	 and	Turkey	(99)	increasing	its	globalization.	Gomez,	et	al	(97)	described	mecCMRSA	in	red	deer	 in	Southern	Spain	(Cádiz)	and	 it	 is	known	that	 these	animals	could	potentially	 transmit	 this	 gene	 to	 other	 animals	 or	 even	 to	 humans.	 This	geographic	 proximity	 to	 Portugal	 alerts	 to	 the	 fact	 that	 prevalence	 in	 Portugal	can	 changed	 quickly.	 This	 possibility	 is	 sufficient	 to	 place	 Portuguese	 clinical	laboratories	in	alert	to	this	problem,	because	molecular	techniques,	such	as	PCR	to	detect	MRSA	or	simpler	techniques	like	slide	agglutination	do	not	detect	this	microorganism.	 With	 the	 use	 of	 these	 methodologies,	 for	 detection	 or	confirmation	of	MRSA,	we	can	obtained	false-negative	results,	and	S.aureus	will	be	erroneously	diagnosed	as	methicillin	susceptible,	potentially	leading	to	wrong	treatment	 decisions,	 increased	 delayed	 response,	 prolonged	 hospital	 stay	 and	overall	 increased	 cost	 of	 hospitalization.	 In	 laboratories	 that	 perform	antimicrobial	susceptibility	tests,	mecCMRSA	will	likely	be	identified	correctly	as	MRSA	 but	 when	 using	 automated	 VITEK2	 system,	 mecCMRSA	 produce	 a	distinctive	antibiotic	 susceptibility	profile	when	compared	 to	mecA	MRSA.	This	problem	 lead	 researchers	 to	 study	mecCMRSA	 isolates	 on	 automated	 VITEK2	
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system	 and	 concluding	 that	mecCMRSA	was	 oxacillin	 susceptible	 and	 cefoxitin	resistant	(65).	With	this	simple	method	used	in	clinical	laboratories	it	is	possible	to	 suspect	 of	 the	 mecCMRSA	 and	 selecting	 the	 isolate	 for	 deeper	 analysis,	namely,	molecular	techniques	with	primers	able	to	amplify	both	mecA	and	mecC	or	only	mecC	gene.	This	strategy	will	also	allow	to	locally	monitoring	the	changes	in	mecCMRSA	 distribution	 and	 prevalence	 over	 time.	 Considering	 that	 contact	with	animals	poses	a	zoonotic	 risk	of	 infection	with	 this	gene	and	 its	 report	 in	neighbouring	Spain	and	France	both	 in	animals	and	humans,	advice	to	monitor	its	 presence	 in	 Portuguese	 hospitals.	 The	 importance	 of	 locally	 monitor	 the	changes	 in	 prevalence	 of	 mecCMRSA	 lead	 us	 to	 perform	 a	 study	 on	 rapid	screening	of	MRSA	carrying	the	mecC	gene	at	the	Centro	Hospitalar	Baixo	Vouga	was	 performed	 during	 research	 period	 (results	 submitted	 for	 peer	 review	 in	international	 journal)	 with	 the	 aim	 of	 evaluate	 the	 presence	 of	 suspected	
mecCMRSA	isolates,	in	Aveiro,	Portugal,	using	a	combination	of	two	methods:	the	slide	agglutination	test	and	VITEK2	profile.	Our	sample	included	a	retrospective	analysis	of	oxacillin	and	cefoxitin	obtained	with	automated	system	among	835	S.	
aureus,	between	January	2014	and	December	2016.	To	test	the	inclusion	of	the	combination	 of	 two	 methodologies	 in	 the	 day-to-day	 activities	 of	 the	 clinical	laboratory	 a	 sample	 of	 84	 MRSA	 strains	 collected	 from	 Medicine	 department	during	 2014	 were	 retested	 for	 slide	 agglutination	 test.	 To	 our	 knowledge	
mecCMRSA	was	not	 yet	 reported	 in	Portugal	 and,	 in	 accordance,	 the	 results	 of	our	study	do	not	suggest	 the	presence	of	mecCMRSA	in	 the	studied	sample	but	highlight	 the	 possibility	 of	 all	 clinical	 laboratories,	 to	 evaluate	 the	 presence	 of	this	microorganism	and	monitor	changes	in	its	prevalence	over	time,	in	a	cheap,	fast	 and	 simple	 away	 using	 standard	 methods,	 even	 for	 countries	 where	
mecCMRSA	was	not	yet	detected.	Monitoring	the	epidemiology	of	this	emerging	form	of	MRSA	through	persistent	evaluation	 of	 mecC	 prevalence	 in	 humans	 and	 animals	 is	 fundamental	 to	stimulate	 the	 development	 of	 procedures	 that	 allow	 the	 correct	 diagnostic	 of	
mecCMRSA.	 This	 effort	 will	 contribute	 to	 adequate	 treatment	 decisions	 when	managing	 MRSA	 infection	 and	 reduced	 the	 overall	 increased	 cost	 of	hospitalization	if	mecCMRSA	arrives	to	Portugal.	
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There	are	differences	described	by	Kim	et	al	in	biochemistry	between	mecA	and	
mecC	encoded	PBP2a	(63).	The	therapeutic	implications	of	mecC	have	not	been	reported,	 but	 this	 variant	 PBP	 has	 a	 higher	 affinity	 for	 penicillins	 than	 for	cephalosporins,	 and	 in	 vitro,	mecC	 isolates	 are	 susceptible	 to	 the	 addition	 of	clavulanate	to	penicillin	(19,	106).	This	treatment	may	be	a	choice	in	future	as	an	alternative	 to	 the	 “gold	 standard”	 vancomycin.	 This	 is	 particularly	 important	given	 the	 increasing	 challenges	 posed	 by	 multidrug	 resistance	 and	 offers	 a	hypothesis	for	confronting	an	emerging,	resistant	bacterial	pathogen	with	an	old	antibiotic	(106).		As	mention	S.aureus	 is	 a	 leading	 cause	 of	 nosocomial	 infections	 and	 treatment	response	 could	 be	 influenced	 by	 increase	 in	 vancomycin	MIC	 values.	 Previous	studies	have	shown	an	association	between	high	vancomycin	MIC	and	treatment	failure	or	mortality	(107-110)	other	studies	shown	either	an	inverse	association	(111)	or	a	lack	of	association	(86,	112).	The	results	are	inconsistent	since	they	do	not	 show	 a	 close	 relationship	 between	 the	MIC	 value	 and	 the	 outcome	 (113).	Interestingly,	some	studies	suggest	that	MRSA	strains	with	elevated	vancomycin	MICs	may	be	less	virulent	than	strains	with	lower	MICs	(110,	113).	Alterations	in	the	 cell	 wall	 structure	 and	 the	 low	 virulence	 of	 MRSA	 isolates	 with	 high	vancomycin	MIC	 could	be	 related	 (110).	 In	 some	 studies	 it	was	 suggested	 that	the	 thickness	of	 the	cell	wall	 in	 isolates	with	high	vancomycin	MICs	covers	 the	teichoic	 and	 lipoteichoic	 acids,	 inhibiting	 the	 immune	 activation	 and,	subsequently,	the	development	of	shock.	Additionally,	MRSA	isolates	with	a	high	MIC	 have	 been	 related	 with	 a	 slow	 growth	 rate	 and	 a	 loss	 of	 function	 of	 the	accessory	 gene	 regulator	 operon	 (agr)	 that	 controls	 several	 virulence	 factors	(114).	 Thus,	 there	 seems	 to	 be	 a	 relationship	 between	 pathogenicity	 and	resistance	 to	 vancomycin.	 Loss	 of	 function	 of	 the	 accessory	 gene	 regulator	operon	might	confer	a	survival	advantage	to	MRSA	under	vancomycin	pressure,	mainly	 in	 isolates	 with	 the	 accessory	 gene	 regulator	 group	 II	 genotype	 (110,	115).		In	 recent	 years,	 it	 has	 been	 described	 a	 phenomenon	 called	MIC	 creep,	which	describes	 the	 increase	of	 the	minimum	inhibitory	concentration	of	vancomycin	in	the	susceptibility	range.	This	issue	started	to	be	studied	in	various	hospitals,	mainly	in	Europe,	to	identify	the	best	methods	to	evaluate	and	the	variables	that	
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affect	it.	In	Portugal,	the	investigation	of	this	phenomenon	is	still	residual,	only	a	study	with	data	from	Lisbon	region	between	January	2007	and	December	2009	was	published	and	it	reports	data	not	compatible	with	the	presence	of	MIC	creep	during	the	studied	period	(116).		There	are	researches	with	contradictory	results	when	studying	vancomycin	MIC	creep	 with	 MRSA.	 Some	 studies	 report	 MIC	 creep	 in	 some	 regions	 and	 large	multicenter	 surveillance	 studies	 do	 not	 relate	 similar	 findings	 over	 time	 (116-118).	Our	research	aimed	to	compare	the	population	of	Centro	Hospitalar	Baixo	Vouga,	Aveiro,	with	results	already	published	at	national	and	international	level	and	produce	information	that	will	help	monitoring	this	phenomenon.	The	study	“Evaluation	 of	 vancomycin	 MIC	 creep	 in	 Staphylococcus	 aureus	 infections	 –	 a	meta-analysis”	assessed	the	global	evidence	of	vancomycin	MIC	creep	recurring	to	 meta-analysis	 method.	 The	 sample	 included	 single	 and	 large	 multicenter	reports	published	in	Pubmed	database.	The	results	showed	that	mean	values	of	vancomycin	MICs,	of	all	MRSA	isolates	reported,	were	1.19	mg/L	and	1.20	mg/L	determined	by	Etest	and	BMD	method,	respectively.		When	 considering	 pooled	mean	 of	 vancomycin	 MIC	 over	 time,	 it	 was	 showed	that	 studies	 published	 before	 the	 year	 2000	 exhibited	 the	 highest	 vancomycin	MICs	and	after	2007	the	vancomycin	MICs	showed	a	slight	decrease.	The	results	were	 similar	 for	 the	 two	 selected	 MIC	 methods,	 BMD	 and	 Etest.	 Correlations	between	 MIC	 testing	 methods	 effect	 and	 time	 strata	 were	 studied	 and	 no	evidence	 of	 MIC	 creep	 were	 observed.	 When	 analyzing	 MRSA	 isolates	 that	reported	 vancomycin	 MIC	 ≥	 2	 mg/L	 over	 time	 strata,	 both	 BMD	 and	 Etest	methods	show	a	decrease	in	vancomycin	MIC,	strengthening	the	observation	of	no	evidence	of	MIC	creep.		It	is	important	to	understand	that	data	from	multiple	centres	can	obscure	trends	that	may	exist	within	a	given	institution	or	country,	as	a	result	of	differences	in	patient	 populations	 and	 drug	 usage	 patterns.	 However,	 the	 negative	 values	 of	Spearman´s	 correlation	 obtained	 in	 our	 meta-analysis	 support	 no	 evidence	 of	vancomycin	MIC	creep.		Analyse	vancomycin	MIC	creep	 linked	to	a	regional	problem	and	evaluate	 local	susceptibility	profiles	 is	 important	 to	created	data	 that	will	help	 in	 local	MRSA	infection	 clinical	 management.	 Kehrmann	 et	 al.,	 assessed	 the	 vancomycin	 MIC	
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distribution	 for	MRSA	blood	culture	 isolates	during	6	years	 in	Germany.	MRSA	isolates	were	collected	at	several	hospitals	 in	two	German	cities	and	MIC	creep	phenomenon	 was	 detected	 only	 in	 one	 city,	 suggesting	 that	 this	 phenomenon	could	be	a	regional	problem	and	recommending	that	all	hospitals	should	monitor	their	 local	status	 (118).	To	evaluate	 this	hypothesis	 in	 the	study	“Evaluation	of	vancomycin	MIC	creep	 in	Staphylococcus	aureus	 infections”	we	aimed	 to	assess	vancomycin	MIC	distribution	for	S.aureus	infections,	over	a	period	of	four	years,	in	 Centro	Hospitalar	 Baixo	Vouga,	 Aveiro,	 Portugal	 and	 evaluate	 differences	 in	vancomycin	 MIC	 through	 the	 application	 of	 different	 susceptibility	 testing	methods.	 The	 results	 showed	 significant	 differences	 of	 vancomycin	 MIC	 by	difference	methods	 but	 do	 not	 suggest	 the	 presence	 of	 vancomycin	MIC	 creep	during	 the	 study	period.	These	 results	 showed	 that	vancomycin	MICs	 from	 the	automated	method	were	 also	 significantly	 lower	 than	 those	 found	by	 the	BMD	analysis.	It	 is	 important	to	highlight	that	real	MIC	assayed	by	means	of	Etest	or	BMD	 is	 more	 useful	 than	 that	 provided	 by	 the	 automated	 method	 (5).	 These	findings	are	consistent	with	the	results	obtained	in	the	study	of	Tomczak	H.	et	al	that	 compared	 MIC	 obtained	 with	 the	 automated	 method	 and	 with	 the	 Etest	method	 for	S.aureus	 strains	 isolated	 from	clinical	materials	and	concluded	 that	results	obtained	with	automated	method	were	lower	(5).		These	 results	and	knowing	 that	 the	 type	of	microbiological	 susceptibility	used,	type	 of	 S.aureus	 strain	 examined	 or	 type	 of	 patient	 population	 evaluated,	may	influence	MIC	creep	phenomenon,	we	suggest	 that	all	hospitals	should	monitor	their	 local	 status	 of	 vancomycin	 MICs	 to	 evaluate	 the	 presence	 of	 trends	 and	ensure	 the	 effectiveness	 of	 therapy	with	 vancomycin,	 preferably	with	 Etest	 or	BMD	methods.		At	 Centro	 Hospitalar	 Baixo	 Vouga,	 Aveiro,	 we	 can	 conclude	 that	 treatment	decisions	 and	 vancomycin	 MIC	 value	 are	 being	 applied	 in	 a	 way	 that,	 for	 the	period	 studied,	 did	 not	 create	 a	 MIC	 creep	 phenomenon,	 suggesting	 that	management	 MRSA	 infection	 with	 vancomycin	 is	 on	 the	 right	 path.	 The	importance	 of	 vancomycin	 MIC	 in	 the	 prognosis	 of	 MRSA	 infection	 is	 widely	recognized,	as	there	is	clear	evidence	of	loss	of	efficacy	of	vancomycin	with	MIC	greater	 than	 or	 equal	 to	 1mg/ml,	 justifying	 the	 use	 of	 other	 drugs,	 namely	
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linezolid,	daptomycin	and	tigecycline,	especially	when	the	infection	is	located	in	organs	where	the	penetration	of	the	antibiotic	is	more	complex.		The	correct	antibiotic	 therapy	used	 in	a	early	stage	 is	essential	 in	 treatment	of	patients.	 But,	 in	 the	majority	 of	 cases,	 the	 initial	 decision	 about	 the	 antibiotic	therapy	 is	 made	 empirically,	 while	 awaiting	 the	 microbiology	 results.	 Current	evidence	 is	 insufficient	 to	 support	 empiric	 use	 of	 alternative	 agents	 such	linezolid	or	daptomycin,	for	reasons	like:	broader	use	of	these	alternative	agents	will	 likely	 lead	 to	 increasing	 resistance	 to	 them;	 frank	 vancomycin	 resistance	remains	rare	and	only	a	fraction	of	the	patients	with	suspected	MRSA	showed	a	vancomycin	 MIC	 high	 but	 in	 the	 susceptible	 range.	 Nevertheless,	 is	 extremely	relevant	 that	 our	 institution	 continues	 to	 monitor	 the	 vancomycin	 MICs	 to	evaluate	 the	 possible	 presence	 of	 trends	 in	MIC	 over	 time,	 allowing	 antibiotic	therapy	choices	as	accurate	as	possible.	Either	with	the	evaluation	of	the	MIC	values	of	vancomycin	or	with	research	of	the	mecC	 gene	 in	 S.	 aureus,	 the	 purpose	 of	 this	 work	 is	 based	 on	 the	 need	 to	better	 understand	 the	 resistance	 of	 nosocomial	 infections	 to	 antibiotics	 and	 to	alert	 clinicians	 to	 the	 possibility	 of	 resistance	 to	 vancomycin	 scenario	 and	 the	microbiology	 laboratories	 for	 the	 risk	 of	 new	 strains	 carrying	 the	 resistance	genes.		In	 conclusion,	 the	 discovery	 of	 the	mecC	 gene	 can	 represent	 a	 public	 health	threat	and	although	this	gene	was	not	detected	in	Portugal	it	is	important	that	all	laboratories	should	revise	the	diagnostic	protocols	for	this	new	gene.	This	gene	was	 mainly	 found	 in	 livestock-associated	 MRSA	 and	 its	 prevalence	 is	 clearly	increasing	since	it	was	reported.	The	therapeutic	implications	of	mecC	have	not	been	 reported,	 but	 there	 are	 speculations	 about	 the	 treatment	 of	 this	 new	variant	 with	 old	 antibiotics	 that	 could	 be	 an	 alternative	 to	 the	 gold	 standard	vancomycin.	On	the	other	hand,	no	evidence	of	vancomycin	MIC	creep	was	found,	either	in	the	meta-analysis	 or	 in	 our	 institution.	 Even	 so,	 these	 results	must	 be	 considered	when	 interpreting	 vancomycin	 susceptibility	 and	 during	 discussions	 about	alternative	 antistaphylococcal	 agents	 for	 patients	 because	 the	 present	 strategy	cloud	work	today	but	became	ineffective	rapidly	if	MIC	creep	emerge	inside	the	institution.	
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Part	IV. Future	perspectives		
	Monitor	 the	 presence	 of	mecCMRSA	 in	 regions	with	 high	 prevalence	 of	MRSA,	should	be	consider	and	Portugal,	a	country	with	high	MRSA	prevalence,	is	a	good	example	for	that.	The	zoonotic	risk	of	mecCMRSA	infections	motivates	the	future	evaluation	 of	 its	 prevalence	 between	 different	 livestock	 species.	 It	 is	 also	important	to	understand,	for	future	studies,	their	role	in	animal	diseases	and	its	zoonotic	transmission	mechanism.	The	link	of	mecC	to	the	resistance	mechanism	and	 to	 the	 susceptibility	 of	 the	 strain	 on	 antibiotic	 treatment	 must	 also	 be	evaluated	 since	 it	 is	 foreseen	 that	 it	 will	 probably	 contribute	 for	 the	 future	difficulties	 that	 society	 will	 need	 to	 transpose	 when	 managing	 bacterial	resistance.	 In	 this	 spectrum,	 the	 implementation	 of	 systematic	 review	 of	susceptibility	 profiles	 of	 bacteria	 to	 antibiotics	 must	 became	 permanent	 and	made	 locally	 to	 better	 understand	 the	 differences	 between	 regions	 and	populations.	 The	 evaluation	 of	 vancomycin	 MIC	 trend	 in	 our	 hospital	demonstrates	 utility	 to	 the	 health	 professional	 that	 work	 with	 this	 antibiotic.	Reproduce	 this	 approach	 systematically	 for	 vancomycin	 in	 other	 Portuguese	hospitals	 and	 also	 to	 other	 susceptibility	 situation	 is	without	 doubts	 a	 road	 to	take	in	future	research.						 	
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